

CURRICULUM VITAE

Cognome : **VOLPES**
Nome : **Riccardo**
Luogo e Data di nascita : Palermo, 24/11/1959
CF : VLPRCR59S24G273D
Nazionalità : Italiana
Indirizzo : Via Siracusa n.32
90141 Palermo (ITALIA)
E-mail : riccardovolpes24@gmail.com;
Pec : riccardovolpes@pec.it;
Iscrizione albo Prov. PA : PA 8670

Curriculum e Formazione:

Liceo:

1972-1977 Liceo Classico "Umberto I", Palermo.

Università:

1977-1983 Facoltà di Medicina, Università di Palermo 20/07/1983: *Laurea in Medicina e Chirurgia* (voto finale: 110/110, con lode e menzione speciale della Tesi).

1983-84 Abilitazione all'esercizio delle professione medica presso Università di Palermo.

1983-1987 Scuola di Specializzazione in Malattie dell'Apparato Digerente alla Facoltà di Medicina, Università di Palermo.
12/12/1987 Diploma di Specializzazione in Malattie dell'Apparato Digerente (voto finale: 50/50 con lode).

1988-1992 Assistente Ricercatore a tempo pieno presso il Dipartimento di Anatomia Patologica, Laboratorio di Istochimica e Citochimica, Ospedale Universitario Sint-Rafaël, Università Cattolica di Leuven (Belgium).
28/11/1991: Diploma e Titolo di Ph.D. ("*Geaggregeerde voor het Hoger Onderwijs in Geneeskunde*") all'Università Cattolica di Leuven (Belgium).

Formazione e Training:

- 1980-1983 Studiante interno a tempo pieno come tirocinio presso la Clinica Medica R, Università di Palermo, Ospedale V. Cervello, Palermo (Italy).
- 1980-1984 1983-1987 Studiante interno a tempo pieno come tirocinio per la Scuola di Specializzazione in Malattie dell'Apparato Digerente presso la Clinica Medica R, Università di Palermo, Ospedale V. Cervello, Palermo (Italy).
- 1980-1985 1987-1988 Tirocinio post-specializzazione presso la Clinica Medica R ed il Centro Trapianti di Fegato, Università di Palermo, Ospedale V. Cervello, Palermo (Italy).

Ruoli professionali:

- 1988-1993 Assistente Ricercatore di ruolo a tempo pieno nell'Unità di Immunopatologia del Fegato, presso il Dipartimento di Anatomia Patologica, Laboratorio di Istochimica e Citochimica, Ospedale Universitario Sint-Rafaël, Università Cattolica di Leuven (Belgium).
- 1994-2000 Dirigente Medico 1° livello a tempo pieno presso il Dipartimento di Gastroenterologia ed Endoscopia Digestiva, Azienda Ospedaliera S. Giovanni Battista, Torino (Italy).
- 1996-2000 Professore associato presso la Scuola di Specializzazione in Gastroenterologia, Epatologia ed Endoscopia Digestiva (diretta dal Prof. M. Rizzetto) Università di Torino (Italy).
- 2000-2016 Dirigente Medico 2° livello in Epatologia e Gastroenterologia, Unità di Epatologia e Gastroenterologia, Dipartimento di Medicina, Istituto Mediterraneo dei Trapianti e delle Terapie ad Alta Specializzazione (ISMETT) – Palermo.
Professore Associato di Medicina al Dipartimento di Medicina UPMC (University of Pittsburg Medical Center), Pittsburg, USA.
- 2016-2019 Responsabile dell'Unità di Epatologia e Gastroenterologia, Dipartimento di Medicina, Istituto Mediterraneo dei Trapianti e delle Terapie ad Alta Specializzazione (ISMETT) – Palermo.
Professore Associato di Medicina al Dipartimento di Medicina UPMC (University of Pittsburg Medical Center), Pittsburg, USA.
- 2019-nov. 2022 Dirigente Medico 2° livello in Epatologia e Gastroenterologia, Unità di Epatologia e Gastroenterologia, Dipartimento di

Medicina, Istituto Mediterraneo dei Trapianti e delle Terapie ad Alta Specializzazione (ISMETT) – Palermo.
Professore Associato di Medicina al Dipartimento di Medicina UPMC (University of Pittsburgh Medical Center), Pittsburgh, USA.

2023 ad oggi

Specialista Epatologo e Gastroenterologo in Libera Professione presso Istituto Fondazione e Giglio – Cefalù (PA).

Titolo Accademico post-specializzazione:

Ph.D. (Geaggregeerde voor het Hoger Onderwijs in Geneeskunde), conseguito il 28.11.1991, presso Catholic University of Leuven (Belgium) con la seguente tesi: Immune adhesion molecules in inflammatory liver diseases. Pubblicazione: Acco University Press; Leuven. October 1991.

Dal 1989 ad oggi:	Membro dell'Associazione Italiana per lo studio del Fegato (AISF).
Dal 2014 ad oggi:	Membro eletto della Commissione Permanente dei Trapianti (CPT) dell'Associazione Italiana per lo studio del Fegato (AISF).
Dal 1999 ad oggi:	Membro dell'Associazione Europea per lo studio del Fegato (EASL).
Dal 2004 ad oggi:	Membro Internazionale dell'Associazione Americana per lo studio del Fegato (AASLD).

Settori specifici di competenza clinica, e di interesse per la ricerca scientifica:

- Diagnosi e Trattamento dei pazienti adulti con tutte le tipologie di Malattie del Fegato e delle Vie Biliari.
- Gestione clinica integrata dei pazienti adulti con Malattie del Fegato e delle Vie Biliari in fase complicate o terminale.
- Gestione clinica integrata dei pazienti adulti dopo Trapianto di Fegato
- Gestione dei pazienti acuti e cronici ricoverati in Unità di Terapia Intensiva (insufficienza epatica acuta ed epatiti fulminanti, uso di fegati bio-artificiali all'interno di protocolli clinici dedicati)

- Anatomia Patologica ed Istopatologia del Fegato
- Immunopatologia, Immunoistochimica e Citochimica del Fegato
- Aspetti medici pre- e post-chirurgici per chirurgia epato-biliare e chirurgia mini-invasiva addominale e ricostruttiva
- Onologia epatobiliare
- Investigatore Principale di numerosi Studi Clinici Controllati (Clinical Trials) e protocolli scientifici sperimentali in ambito epatologico.
- Esperienza completa e competenza nella gestione di Studi Clinici Controllati (Clinical Trials) e condotti secondo la "Good Clinical Practice".
- Attiva partecipazione in protocollo e progetti di Ricerca e di Formazione nell'ambito delle Terapie innovative per le Malattie di Fegato acute e croniche (terapie antivirali, trattamento di epatiti autoimmuni, terapie di epatopatie acute e croniche su base alcolica, diagnosi e terapie per cirrosi biliari primitive e colangite sclerosante primaria, profilassi di epatite virale di tipo C e B prima e dopo trapianto di fegato, uso sperimentale di farmaci immunosoppressori dopo trapianto di fegato, trattamento delle neoplasie primitive e secondarie del fegato).

Publicazioni come ARTICOLI completi

1. Pagliaro L, Maisano S, *Volpes R*. Dimensione del problema: storia naturale dell'epatite da virus B. In: Vaccinoprofilassi dell'infezione da virus dell'epatite B. E Pisi, CA Busachi, G Realdi, AR Zanetti, Eds. Bologna. 1983; 9-23.
2. Pagliaro L, Maisano S, *Volpes R*. Fattori di rischio in gastroenterologia. In: Aggiornamenti di Gastroenterologia. Scuro LA, Vantini I (Eds). Il Pensiero Scientifico Editore. Roma. 1984; 1-22.
3. D'Amico G, Morabito A, Pagliaro L, *Volpes R*. Six-week prognostic indicators in upper gastrointestinal haemorrhage in cirrhosis. *Frontiers in Gastrointestinal Research*. 1986; 9:247-257.
4. Pagliaro L, Craxi' A, *Volpes R*. Epatiti croniche: indici predittivi della storia naturale e post-terapeutica. XII Riunione annuale di Informazione Epatologica. Chianciano, 1987.
5. Craxi' A, Di Marco V, *Volpes R*, Palazzo U. Anti-alpha-interferon antibodies after interferon treatment in patients with chronic viral hepatitis. *Hepato-Gastroenterology* 1988; 35:210-214.
6. Craxi' A, Di Marco V, *Volpes R*, Bruno R, Maggio A. Alpha-interferon and posttransfusion Non A, Non B hepatitis. *Lancet* 1989; II:391-392.
7. Craxi' A, *Volpes R*. Epidemiologia e presentazione clinica delle epatiti croniche in Italia. In: Progressi clinici in Medicina. Protocolli diagnostici in Gastroenterologia. Ed. R Naccarato. Piccin Editore Padova. 1989; vol. 4/5; 137-146.
8. Di Marco V, Bruno R, *Volpes R*, Spataro G, Palazzo U, Craxi' A. Interferon linfoblastoide a breve e lungo termine nelle epatiti croniche nonA-nonB. Società Italiana di Gastroenterologia, XXVII Congresso Nazionale, Bologna 13-16 Dicembre 1989. Monduzzi Ed. 511-514.
9. Craxi' A, Di Marco V, *Volpes R*, Rizzetto M et al. Treatment with interferon alpha-2b in chronic HDV hepatitis in children. *J Hepatol* 1990; 11:175-176.
10. *Volpes R*, van den Oord JJ, Desmet VJ. Adhesive molecules in liver disease. Immunohistochemical distribution of thrombospondin receptors in chronic HBV infection. *J Hepatol* 1990; 10:297-304.
11. *Volpes R*, van den Oord JJ, Desmet VJ. Immunohistochemical study of adhesion molecules in liver inflammation. *Hepatology* 1990; 12:59-65.
12. *Volpes R*, van den Oord JJ, Desmet VJ. Hepatic expression of Intercellular Adhesion Molecule-1 (ICAM-1) in viral hepatitis B. *Hepatology* 1990; 12:148-154.
13. *Volpes R*, van den Oord JJ, De Vos R, Depla E, De Ley M, Desmet VJ. Expression of interferon-gamma receptor in normal and pathological human liver tissue. *J Hepatol* 1991; 12:195-202.

14. *Volpes R, van den Oord JJ, Desmet VJ.* Memory T-cells represent the predominant lymphocyte subset in acute and chronic liver inflammation. *Hepatology* 1991; 13:826-829.
15. *Lauweryns B, van den Oord JJ, Volpes R, Foets B, Missotten L.* Distribution of VLAIntegrins in the human cornea: an immunohistochemical study using monoclonal antibodies. *Investigative Ophthalmology and Visual Science* 1991; 32:2079-2085.
16. *Volpes R, van den Oord JJ, Desmet VJ.* Distribution of the Very Late Activation (VLA) family of Integrins in normal and pathological human liver tissue. *Gastroenterology* 1991; 101:200-206.
17. *Volpes R, van den Oord JJ, Van Damme B, Desmet VJ.* CD14 as a marker for liver allograft rejection? *Lancet* 1991; 337 (i); 8732:60.
18. *van den Oord JJ, Volpes R, Desmet VJ.* Intrahepatic T-cells in chronic HBV-infection. Their adhesive properties and effect on the phenotype of near-by hepatocytes. In: *Frontiers of Mucosal Immunology*, vol. II. Tsuchiya M, Nagura H, Hibi T, Moro I (Eds.). Elsevier Science Publishers B.V., Amsterdam. 1991, pp. 79-82.
19. *van den Oord JJ, Volpes R, Desmet VJ.* Dendritic cells and the liver. *APMIS* 1991; 23:6876.
20. *Volpes R, van den Oord JJ, Desmet VJ.* Lymphocyte trafficking in inflamed liver. *APMIS* 1991; 23:53-67.
21. *Craxì A, Di Marco V, Volpes R, Rizzetto M.* Treatment with recombinant alpha-2b of chronic HDV hepatitis in children. In: *The Hepatitis Delta Virus*. Gerin JL, Purcell RH, Rizzetto M (Eds.). Wiley-Liss Publishers, New York 1991, pp. 399-404.
22. *Craxì A, Di Marco V, Volpes R, Marra S, Rizzetto M, Rosina F, Barbera C, Bortolotti F, Crivellaro C, Iannuzzi C, Calzia R, Giacchino R, Timitilli A, Vajro P, Fontanella A, Pintus C.* Treatment with recombinant alpha-2b-interferon of chronic HDV hepatitis in children. *Prog Clin Biol Res* 1991; 364P:399-404.
23. *Volpes R, van den Oord JJ, Desmet VJ, Yap S-H.* Induction of intercellular adhesion molecule-1 (CD54) on human hepatoma cell line HepG2: influence of cytokines and hepatitis B virus-DNA transfection. *Clin Exp Immunol* 1992; 87:71-75.
24. *Volpes R, van den Oord JJ, Desmet VJ.* Vascular adhesion molecules in acute and chronic liver inflammation. *Hepatology* 1992; 15:269-275.
25. *Volpes R, van den Oord JJ, De Vos R, Desmet VJ.* Hepatic expression of type A and type B receptors for tumor necrosis factor. *J Hepatol* 1992; 14:361-369.
26. *Volpes R, van den Oord JJ, Desmet VJ.* LAM-1/Leu-8 antigen is expressed on portal, but not on lobular intrahepatic mononuclear cells in inflammatory liver diseases. *Clin Exp Immunol* 1992; 88:50-55.

27. Foets BJJ, van den Oord JJ, *Volpes R*, Missotten L. In-situ immunohistochemical analysis of cell adhesion molecules on human corneal endothelial cells. *Br J Ophtalmol* 1992; 76:205-209.
28. *Volpes R*, van den Oord JJ, Desmet VJ. Homing of T-lymphocytes in acute and chronic HBV positive inflammatory liver disease. *Arch Virol* 1992; 4:42-45.
29. *Volpes R*, van den Oord JJ, Desmet VJ. Can hepatocytes serve as "activated", immunomodulating cells in the immune response? *J Hepatol* 1992; 16:228-240.
30. *Volpes R*, van den Oord JJ, Desmet VJ. Integrins as differential cell lineage markers of primary liver tumors. *Am J Pathol* 1993; 142:1483-1492.
31. van den Oord JJ, *Volpes R*, Desmet VJ. Cytokines, adhesion molecules and HLA-expression in chronic hepatitis. *J Hepatol* 1996; 54:33-38.
32. Magrin S, Craxì A, Fabiano C, Simonetti R, Fiorentino G, Marino L, Diquattro O, Di Marco V, Lo Iacono O, *Volpes R*, et al. Hepatitis C viremia in chronic liver disease: relationship to interferon-alpha or corticosteroid treatment. *Hepatology* 1994; 19:273279.
33. *Volpes R*. Molecole di adesione immunitaria nelle malattie infiammatorie del fegato. *Minerva Gastroenterol Dietol* 1995; 40:25-34.
34. *Volpes R*. Adhesion molecules and chronic viral hepatitis. *Minerva Gastroenterol Dietol* 1995; 41:39-43.
35. *Volpes R*, David E. Aspetti istologici dell'epatite da virus C. In: *Il virus dell'epatite C (HCV): l'infezione e la malattia*. Eds. A. Craxì, P. Almasio, S. Magrin. Roche Diagnostics System. 1996, vol. 2:67-81.
36. *Volpes R*. Adhesion molecules in viral hepatitis. *Hepato-Gastroenterology* 1996; 43:11061108.
37. Craxì A, Di Marco V, Lo Iacono O, Almasio P, Bruno R, Cammà C, *Volpes R*, Pagliaro L. Transfusion-associated chronic hepatitis C: alpha-1 interferon for 6 vs. 12 months. *J Hepatol* 1996; 24:539-546.
38. Colombatto P, Randone A, Civitico G, Monti Gorin G, Dolci L, Medaina N, Calleri G, Oliveri F, Baldi M, Tappero G, *Volpes R*, David E, Verme G, Smedile A, Bonino F, Brunetto MR. A new hepatitis C virus-like flavivirus in patients with cryptogenic liver disease associated with elevated GGT and alkaline phosphatase serum levels. *J Viral Hepat* 1997; 4:55-60.
39. Magrin S, Craxì A, Fabiano C, Marino L, Fiorentino G, Lo Iacono O, *Volpes R*, Di Marco V, Almasio P, Vaccaro A, Urdea MS, Wilber JC, Bonura C, Gianguzza F, Capursi V, Filiberti S, Stuyver L, Pagliaro L. HCV viraemia is more important than genotype as a predictor of response to interferon in Sicily (South Italy). *J Hepatol* 1996; 5:583-590.
40. *Volpes R*. Malattie epatiche da accumulo: Malattia di Wilson ed Emocromatosi ereditaria. In: *Epatiti Croniche*, M. Rizzetto Ed. Il Pensiero Scientifico Editore. 1997; 12:32-38.

41. Actis GC, Ciancio A, Lagget M, Marzano A, Ottobrelli A, Torrani MR, *Volpes R*, Rizzetto M, Verme G. La ciclosporina nel trattamento della rettocolite ulcerosa refrattaria al cortisone. Risultati dello studio condotto dal 1990 al 1997 all'Ospedale San Giovanni Battista di Torino. *Minerva Gastroenterol* 1998; 44:163-166.
42. Actis GC, Ciancio A, Lagget M, Marzano A, Ottobrelli A, Torrani-Cerenzia MR, *Volpes R*, Rizzetto M, Verme G. Cyclosporin for steroid refractory ulcerative colitis. Results of a study conducted at Turin General Hospital between 1990 and 1997. *Minerva Gastroenterol Dietol* 1998; 44:163-166.
43. Actis GC, *Volpes R*, Rizzetto M. Oral microemulsion cyclosporin to reduce steroids rapidly in chronic active ulcerative colitis. *Eur J Gastroenterol Hepatol* 1999; 11:905-908.
44. Tassopoulos NC, *Volpes R*, Pastore G, Heathcote J, Buti M, Goldin RD, Hawley S, Barber J, Condreay L, Gray DF. Efficacy of lamivudine in patients with Hepatitis Be antigen negative/Hepatitis B virus DNA positive (pre-core mutant) chronic hepatitis B. *Hepatology* 1999; 29:889-896.
45. Rizzetto M, *Volpes R*. *Le Epatiti Croniche*. Il Pensiero Scientifico Ed. 1999.
46. Actis GC, *Volpes R*, Aimo G, Priolo G, Moscato D, Rizzetto M, Pagni R. Cyclosporin for corticosteroid-refractory ulcerative colitis. Refinement of current treatment modalities. Proceedings of Falk Symposium N.111, "IBD at the end of its first century". Freiburg, June 1999. Kluwer Academic Publishers, 2000.
47. Actis GC, *Volpes R*, Rizzetto M. Two discrete populations of patients with steroidunresponsive ulcerative colitis are identified by their indication to treatment but respond equally to oral microemulsion cyclosporin. *Eur J Gastroenterol Hepatol* 1999; 11:905-908.
48. *Volpes R*. New antiviral treatments in chronic hepatitis B. In: *Epatiti Croniche*, M. Rizzetto Ed. Il Pensiero Scientifico Editore, 1999.
49. Actis GC, *Volpes R*, Marzano A, Ottobrelli A, Modena V, Fusaro E, Rizzetto M. Oral microemulsion cyclosporin for problematic immune-based disease. *Eur J Gastroenterol Hepatol* 2000, 44:320-325.
50. *Volpes R*, Rizzetto M, Smedile A. Response of pre-core mutant chronic hepatitis B infection to lamivudine. *J Med Virol*. 2000 Jul; 61(3):398-402.
51. Rizzetto M, *Volpes R*, Smedile A. Response of pre-core mutant chronic hepatitis B infection to lamivudine. *J Med Virol* 2000; 61:398-342.
52. Leone N, *Volpes R*, Carrera M, Pellicano R, De Paolis P, Fiorentino M, Fronda GR, Rizzetto M. Hepatocellular carcinoma in a non-cirrhotic liver. Two case reports and literature review. *Panminerva Med*. 2000 Jun; 42(2):151-4.
53. Mitchell SA, Grove J, Spurkland A, Boberg KM, Fleming KA, Day CP, Schrupf E, Chapman RW, Pares A, Rodés J, Caballerie L, Bergquist A, Glaumann H, Hultcrantz R, Olerup O, Olsson R, Saarinen S, Scheynius A, Broome U, Boberg KM, Clausen OP, Egeland T, Fausa O, Halstensen T, Knutsen I, Lundin KEA, Spurkland A, Schjolberg A,

- Fleming K, Mitchell SA, Bauducci M, Marchisio B, Recchia S, Rocca G, *Volpes R*, Rosina F. Association of the tumour necrosis factor α -308 but not the interleukin 10-627 promoter polymorphism with genetic susceptibility to primary sclerosing cholangitis. *Gut* 2001; 49:288-294.
54. Cintorino D, Spada M, Clarizia S, Vasta F, Mandalà L, Aricò M, Traverso G, Luca A, Panarello G, Minervini M, Gruttadauria S, Verzaro R, *Volpes R*, Scotti Foglieni C, Gridelli B. Pediatric liver transplantation: preliminary results at Istituto Mediterraneo Trapianti e Terapie ad Alta Specializzazione. *Transplant Proc* 2005; 37:2597-8.
 55. Gruttadauria S, Cintorino D, Mandalà L, Musumeci A, *Volpes R*, Vizzini GB, Palazzo U, Spada M, Verzaro R, Gridelli B. Acceptance of marginal liver donors increases the volume of liver transplant: early results of a single-center experience. *Transplant Proc* 2005; 37:2567-8.
 56. Gruttadauria S, Cintorino D, Piazza T, Mandalà L, Doffria E, Musumeci G, Di Trapani G, Arcadipane A, Scianna G, Spada M, Verzaro R, *Volpes R*, Vizzini G, Palazzo U, Minervini M, Marsh JW, Marcos A, Gridelli B. A safe immunosuppressive protocol in adult-to-adult living-related liver transplantation. *Transplant Proc* 2006; 38: 1106-1108.
 57. Cintorino D, Spada M, Gruttadauria S, Riva S, Luca A, *Volpes R*, Vizzini G, Arcadipane A, Henderson K, Verzaro R, Foglieni CS, Gridelli B. In situ split liver transplantation for adult and pediatric recipients: an answer to organ shortage. *Transplant Proc* 2006; 38:1096-1098.
 58. Marrone G, Caruso S, Miraglia R, Tarantino I, *Volpes R*, Luca A. Percutaneous transarterial embolization of extrahepatic arteroportal fistula. *World J Gastroenterol* 2006; 12:5562-5564.
 59. Gruttadauria S, Marsh JW, Cintorino D, Biondo D, Luca A, Arcadipane A, Vizzini G, *Volpes R*, Marcos A, Gridelli B. Adult to Adult Living Related Liver Transplant: Report on an Initial Experience in Italy. *Dig Liv Dis* 2007; 39:342-350.
 60. Gruttadauria S, Mandalà L, Petridis I, Luna E, Miraglia R, Caruso S, Vizzini G, *Volpes R*, Wallis Marsh J, Luca A, Marcos A, Gridelli B. Role of splenic artery embolization in the treatment of small for size syndrome in Adult to Adult Living Related Liver Transplantation. *Clin Transpl* June 2007.
 61. Gruttadauria S, Mandalà L, Biondo M, Spampinato M, Lamonaca V, *Volpes R*, Vizzini G, Wallis Marsh J, Marcos A, Gridelli B. Role of basiliximab in the prevention of acute cellular rejection in adult living-related liver transplantation: a single center experience. *Biologics: Targets and Therapy* 2007; 1:69-73.
 62. Gruttadauria S, Vizzini G, Biondo D, Mandalà L, *Volpes R*, Palazzo U, Gridelli B. Critical Use of Extended Criteria Donor in Adult-to-Adult Whole Liver Transplantation: A Single Center Experience. *Liver Transpl* 2007; 14:220-227.
 63. Gruttadauria S, Mandalà L, Miraglia R, Caruso S, Minervini MI, Biondo D, *Volpes R*, Vizzini G, Wallis Marsh J, Luca A, Marcos A, Gridelli B. Successful treatment of small-for-size syndrome in adult to adult living-related liver transplantation: a single center series. *Clin Transpl* 2007 21:761-766.

64. Di Pisa M, Traina M, Miraglia R, Maruzzelli L, *Volpes R*, Piazza S, Luca A, Gridelli B. A case of biliary stones and anastomotic biliary stricture after liver transplant treated with the rendez – vous technique and electrokinetic lithotritor. *World J Gastroenterol* 2008; 14: 2920-2923.
65. Traina M, Di Pisa M, Miraglia R, *Volpes R*, Gruttadauria S, Luca A, Gridelli B. Single balloon enteroscopy for endoscopic retrograde cholangiography in a patient with an hepaticojejunostomy after liver transplant. *Gastrointestinal Endoscopy*, 2008; in press.
66. Gruttadauria S, Marsh JW, Vizzini G, Di Francesco F, Luca A, *Volpes R*, Marcos A, Gridelli B. Analysis of surgical and perioperative complications in seventy-five right hepatectomies for living donor liver transplantation. *World J Gastroenterol* 2008; 14:3159-3164.
67. Viganò J, Gruttadauria S, Mandalà L, Petridis I, Cintonino D, Li Petri S, Varotti G, Minervini M, *Volpes R*, Biondo D, Vizzini G, Marsh WJ, Marcos A, Gridelli B. The role of basiliximab induction therapy in adult-to-adult-living-related transplantation and deceased donor liver transplantation: a comparative retrospective analysis of a single center series. *Transpl Proc* 2008:1953.
68. Tarantino I, Barresi L, Petridis I, *Volpes R*, Traina M, Gridelli B. Endoscopic Treatment of Biliary Complications after Liver Transplantation. *World J Gastroenterol* 2008; 14:4185-4189.
69. Petridis I, Gruttadauria S, Nadalin S, Viganò J, Di Francesco F, Filì D, Pietrosi G, Montalbano M, D'Antoni A, *Volpes R*, Arcadipane A, Vizzini G, Gridelli B. Liver Transplantation using donors older than 80 years: a single center experience. *Transpl Proc* 2008; 40:1976-1980.
70. Gridelli B, Gruttadauria S, Luca A, Spada M, *Volpes R*, Marsch W, Marcos A. One liver for two: split and living donor liver transplantation for adult and pediatric patients. In: *Recent Advances in Liver Surgery*, 2008: 1-14.
71. Minervini MI, Ruppert K, Fontes P, *Volpes R*, De Vera M, Gruttadauria S, Pipitone L, Marsh GW, Marcos A, Gridelli B, Demetris AJ. Liver Biopsy Findings from Healthy Potential Living Liver Donors. Reasons for Disqualification, Silent Diseases and Correlation with Liver Injury. *J Hepatol* 2009; 50:501-510.
72. Di Pisa M, Traina M, Miraglia R, *Volpes R*, Gruttadauria S, Luca A, Gridelli B. Use of a self-expandable metallic stent for large bile leakage following orthotopic liver transplant. *Endoscopy* 2009; 41:E4-E5, Jan 28.
73. Filì D, Vizzini G, Palazzo U, Luca A, Biondo D, *Volpes R*, Pietrosi G, D'Antoni A, Petridis I, Gridelli B. Clinical burden of screening asymptomatic patients for coronary artery disease prior to Liver Transplantation. *Am J Transplant* 2009; 9:1151-1157.
74. Pietrosi G, Miraglia R, Luca A, Vizzini GB, Filì D, *Volpes R*, D'Antoni A, Petridis I, Maruzzelli L, Biondo D, Gridelli B. Arterial Chemoembolization/embolization and Early Complications after Hepatocellular Carcinoma Treatment: A Safe Standardized Protocol in Selected patients with Child class A and B cirrhotis. *J Vasc Interv Radiol* 2009; 20:896-902.

75. Gruttadauria S, Pagano D, Petridis I, Vizzini G, *Volpes R*, Grossi P, Gridelli B. Hepatitis C virus infection in a living-related liver donor. *Am J Transpl* 2009; 10: 191.
76. Traina M, Tarantino I, Barresi L, *Volpes R*, Gruttadauria S, Petridis I, Gridelli B. Efficacy and safety of fully covered self-expandable metallic stents in biliary complications after liver transplantation: a preliminary study. *Liver Transpl* 2009; 15:1493-1498.
77. Di Pisa M, Miraglia R, *Volpes R*, Gruttadauria S, Traina M. Single balloon enteroscopy for endoscopic retrograde cholangiography in a patient with hepaticojejunostomy after liver transplantation. *Gastroenterol Res Pract* 2010; 2010:May 5.
78. Marzano A, Marengo A, Andreone P, *Volpes R*, Canova D, Cursaro C, Riili A, Fiorentino B, Bacci M, Guazzini S, Burra P. Pharmacokinetics and efficacy of intravenous or intramuscular hepatitis B immunoglobulins in prophylaxis of hepatitis B after liver transplantation. *Minerva Med* 2010; 101:373-83.
79. Tarantino I, Barresi L, Traina M, *Volpes R*, Gridelli B. Transgastric plus transduodenal necrosectomy with temporary metal stents placement for treatment of large pancreatic necrosis. *Pancreas* 2010; 39:269-270.
80. Di Pisa M, Miraglia R, *Volpes R*, Gruttadauria S, Traina M. Single balloon enteroscopy for endoscopic retrograde cholangiography in a patient with hepaticojejunostomy after liver transplant. *Gastroenterol Res Pract*. 2010;20:70.
81. Vizzini G, Gruttadauria S, *Volpes R*, D'Antoni A, Pietrosi G, Fili D, Petridis I, Pagano D, Tuzzolino F, Santonocito M, Gridelli B. Lamivudine monoprophylaxis for de novo HBV infection in HBsAg-negative recipients with HBeAb-positive liver grafts. *Clin Transplant* 2011; 25:77-81.
82. Miraglia R, Maruzzelli L, Minervini MI, *Volpes R*, Vizzini G, Gruttadauria S, Caruso S, Luca A, Gridelli B. Transjugular liver biopsy in liver transplant patients using an 18-gauge automated core biopsy needle. *Eur J Radiol* 2011; 80:269-272.
83. Avolio AW, Cillo U, Salizzoni M, De Carlis L, Colledan M, Gerunda GE, Mazzaferro V, Tisone G, Romagnoli R, Caccamo L, Rossi M, Vitale A, Cucchetti A, Lupo L, *Volpes R*, Gruttadauria S, Nicolotti N, Burra P, Gasbarrini A, Agnes S and Donor-to-Recipient Italian Liver Transplant (D2R-ILTx) Study Group. Balancing donor and recipient risk factor in liver transplantation: the value of D-MELD with particular reference to HCV recipients. *Am J Transpl* 2011; 11:2724-2736.
84. Tarantino I, Traina M, Mocciaro F, Barresi, Curcio G, Di Pisa M, Granata A, *Volpes R*, Gridelli B. Fully covered metallic stents in biliary stenosis after orthotopic liver transplantation. *Endoscopy* 2012; 44:246-250.
85. Franciosi M, Caccamo L, De Simone P, Pinna A, Di Costanzo G, *Volpes R*, Scuderi V, Strignano P, Boccagni P, Burra P, Nicolucci A. Development and validation of a questionnaire evaluating the impact of HBIG prophylaxis on quality of life in liver transplant recipients. *Liver Transpl* 2012; 18:332-339.
86. Miraglia R, Maruzzelli L, *Volpes R*, Luca A. "Transhepatic-transjugular portosystemic approach for transjugular intrahepatic portosystemic shunt placement in a patient with

extensive intra and extrahepatic portal vein thrombosis after partial liver transplantation". *Liver Transpl*, 2012.

87. Ciuni R, Biondi A, Grosso G, Nunanri G, Panascia E, Randisi L, *Volpes R*, Arcadipane A, Basile F, Gridelli B, Gruttadauria S. Nutritional aspects in patient undergoing liver resection. *Updates Surgery* 2011; 63:249-252.
88. Belli L, *Volpes R*, Graziadei I, Fagioli S, Starkel P, Burra P, Alberti A, Gridelli B, Vogel W, Pasulo L, De Martin E, Guido M, De Carlis L, Lerut J, Cillo U, Burroughs AK, Pinzello GB. Antiviral therapy and fibrosis progression in patients with mild-moderate hepatitis C recurrence after liver transplantation. A randomized controlled study. *Dig Liver Dis* 2012; 44:603-609.
89. Gruttadauria S, Pagano D, Cintorino D, Arcadipane A, Traina M, *Volpes R*, Luca A, Vizzini G, Gridelli B, Spada M. Right hepatic lobe living donation: a 12 years single Italian center experience. *World J Gastroenterol* 2013, 19:6353-6359.
90. Angelico M, Nardi A, Marianelli T, Caccamo L, Romagnoli R, Tisone G, Pinna AD, Avolio AW, Fagioli S, Burra P, *Volpes R*, Strazzabosco M, Costa AN and Liver Match Investigators. Hepatitis B-core antibody positive donors in liver transplantation and their impact on graft survival: evidence from the Live Match cohort study. *J Hepatol* 2016; 58:715-723.
91. Pagano D, Cintorino D, Vizzini G, *Volpes R*, Spada M, Gruttadauria S. Young living liver donors: a single center perspective. *Ann Transplant* 2014; 25:104-105.
92. Angelico M, Nardi A, Romagnoli R, Marianelli T, Corradini SG, Tandoi F, Gavrila C, Salizzoni M, Pinna AD, Cillo U, Gridelli B, *Volpes R*, De Carlis LG, Colledan M, Gerunda GE, Costa AN, Strazzabosco M; Liver Match Study Investigators. A Bayesian methodology to improve prediction of early graft loss after liver transplantation derived from the Liver Match study. *Dig Liver Dis* 2014; 46:340.
93. Belli L, Romagnoli R, Nardi A, Marianelli T, Donato F, Corradini S, Iemmolo R, Morelli C, Pasulo L, Rendina M, De Martin E, Ponziani F, *Volpes R*, Strazzabosco M, Angelico M. Recipient female gender is a risk factor for graft loss after liver transplantation for hepatitis C. Evidence from the prospective Liver Match cohort. *Dig Liver Dis* 2015; 47:689-694.
94. Tarantino I, Barresi L, Curcio G, Granata A, Ligresti D, Tuzzolino F, *Volpes R*, Amata M, Traina M. Definitive outcomes of self-expandable metal stents in patients with refractory post-transplant biliary anastomotic stenosis. *Digestive and Liver Disease* 2015; 47:562-565.
95. Cillo U, Burra P, Mazzaferro V, Belli L, Pinna AD, Spada M, Nanni Costa A, Toniutto P, *Volpes R*, et al. A multistep, consensus-based approach to organ allocation in liver transplantation: toward a "blended principle model". *Am J Transpl* 2015; 15: 2552.
96. Belli L, Berenguer M, Cortesi P, Strazzabosco M, Rockenschaub S, Martini S, Morelli C, Donato MF, *Volpes R*, Pageaug GP, Coilly A, Fagioli S, Amaddeo G, Perricone G, Vinaixa C, Berlakovich G, Facchetti R, Polak W, Muiesan P, Duvoux C and European Liver and Intestine Association (ELITA). Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: a European study. *J Hepatol* 2016, 65:524-531.

97. Di Francesco F, Bonsignore P, Martucci G, Pagano D, Cintonino D, Liotta R, Arcadipane A, *Volpes R*, Luca A, Gruttadauria S. Normothermic machine perfusion using an Air/Oxygen mixer for reconditioning a liver from a marginal brain death donor. *Liver Transpl* 2016.
98. De Simone P, Fagioli S, Cescon M, De Carlis L, Tisone G, *Volpes R*, Cillo U and Consensus Panel. Use of everolimus in Liver Transplantation: Recommendations from a working group. *Transpl* 2017; 101:239-251.
99. Burra P, Belli LS, Ginanni Corradini S, *Volpes R*, Marzioni M, Giannini E, Toniutto P. Common issues in the management of patients in the waiting list and after liver transplantation. *Dig Liv Dis* 2017; 49:241-253.
100. Mularoni A, Gallo A, Riva G, Barozzi P, Miele M, Cardinale G, Vizzini G, *Volpes R*, Grossi P, Di Carlo D, Luca A, Trenti T, Luppi M, Conaldi PG. Successful treatment of KSHV Inflammatory Cytokine Syndrome (KICS) following donor derived KSHV infection in a HIV-negative kidney-liver transplant patient and correlations with HHV8-specific T-cell responses and circulating HHV8 miRNome. *Am J Transpl* 2017; 17:2963-2969
101. Belli L, Berenguer M, Cortesi P, Strazzabosco M, Vinaixa C, Facchetti R, Rockenschaub S, Martini S, Morelli C, Donato MF, *Volpes R*, Pasulo L, Pageaug GP, Perricone G, Mazzarelli G, De Nicole S, Fagioli S, Coilly A, Berlakovich G, Duvoux C and European Liver and Intestine Association (ELITA). Delisting HCV infected liver transplant candidates who improved after viral eradication: outcome 2 years after delisting. *Liver International* 2018.
102. Beckebaum S, Herzer K, Bauhofer A, Gelson W, De Simone P, De Man R, Engelmann C, Mullhaupt B, Vionnet J, Salizzoni M, *Volpes R*, Ercolani G, De Carlis L, Angeli P, Burra P, Dufour F, Rossi M, Cillo U, Neumann U, Fischer L, Niemann G, Toti L, Tisone G. Recurrence of Hepatitis B infection in liver transplant patients receiving long-term hepatitis B immunoglobulin prophylaxis. *Ann Transpl* 2018, 23:789-801.
103. Lo Re V, *Volpes R*, Gruttadauria S, Petridis I, Burgio G, Mularoni A, Milazzo MP, Sparacia G, Luca A. Guillain-Barré Syndrome after Orthotopic Liver Transplantation: A Clinical Manifestation of Immune Reconstitution Inflammatory Syndrome? *Clinical Neurology and Neurosurgery*, 2018; 183:140-143.
104. Marzano A, Andreone P, Boccagni P, Burra P, Caneschi F, Conoscitore PF, Coppola C, De Carlis L, Fagioli S, Forte P, Gaeta GB, Iemmolo MR, Mazzola P, Merli M, Parrilli G, Piai G, Piras MR, Salizzoni M, Tamè MR, Tisone G, Toniutto PL, Vennarecci G, *Volpes R*, Zamboni F, Caccamo L and ISPhEB group. Prevalent use of combined prophylaxis of Hepatitis B after liver transplantation in Italy: results of a nationale survey in a large cohort. *Minerca Gastroenterol Dietol* 2018; 64:1-9.
105. Miraglia R, Maruzzelli L, Petridis I, Tuzzolino F, *Volpes R*, Luca A. Transjugular intrahepatic portosystemic shunt in patients with portal hypertensive complications: preliminary experience using a new controlled-expansion e-PTFE covered stent. *Eur Radiol* 2018.
106. Burra P, Giannini EG, Caraceni P, Ginanni Corradini S, Rendina M, *Volpes R*, Toniutto P. The Transplant Hepatologists' Position Paper. Specific issues concerning the management of patients on the waiting list and after liver transplantation: referral,

difficult candidates, nutrition, living related liver transplants, hepatocellular carcinoma, new antivirals for HCV. *Liver International* 2018.

107. Pagano D, Barbera F, Conaldi PG, Seidita A, Di Francesco F, Di Carlo D, Tuzzolino F, *Volpes R*, Luca A, Gruttadauria S. Role of Allelic Imbalance in Predicting the Risk of Hepatocellular Carcinoma Recurrence after Liver Transplantation. *Liver International* 2018.
108. Maruzzelli L, Bilbao JI, Miraglia R, Di Piazza A, Mamone G, Caruso S, Gentile G, Tuzzolino F, Florida G, Petridis I, *Volpes R*, Luca A. Transjugular intrahepatic portosystemic shunt in patients with complications of portal hypertension: a single-centre preliminary experience using a new controlled-expansion e-PTFE covered stent. *Cardiovascular Interventional Radiol*, 2018.
109. *Volpes R*, Burra P, Germani G, Manini MA, Caccamo L, Strignano P, Rizza G, Tamè MR, Pinna AD, Calise F, Migliaccio C, Carrai P, De Simone P, Valentini MF, Lupo G, Cordone G, Picciotto FP, Nicolucci A. Switch from intravenous or intramuscular to subcutaneous hepatitis B immunoglobulin: effect on quality of life after liver transplantation. *Health and Quality of Life Outcomes* 2018.
110. Miraglia R, Maruzzelli L, Di Piazza A, Mamone G, Caruso S, Gentile G, Tuzzolino F, Florida G, Petridis I, *Volpes R*, Luca A. Transjugular intrahepatic portosystemic shunt using the new GORE Viatorr controlled-expansion endoprosthesis: prospective, singlecenter, preliminary experience. *Cardiovascular Interventional Radiol*, 2018, Aug, 2.
111. AISF position paper on HCV in immunocompromised patients. Italian Association for the Study of the Liver (AISF). *Digestive and Liver Disease*; 2018.
112. Miraglia R, Maruzzelli L, Mamone G, Cimò B, Cannataci C, Cortis K, Gerasia R, Petridis I, *Volpes R*, Luca A. Radiation exposure in patients with complete portal vein thrombosis or portal cavernoma underwent transjugular intrahepatic portosystemic shunt. *Radiologia Medica*, 2020.
113. Ligresti D, Barbuscio I, Granata A, Martino A, Amata M, *Volpes R*, Traina M. Endoscopic closure of gastrocolocutaneous fistula following percutaneous endoscopic gastrostomy by overstretch endoscopic suturing system. *Endoscopy* 2019; Jul 5.
114. Pietrosi G, Russelli G, Barbera F, Curcio G, Tuzzolino F, Gallo A, *Volpes R*, Vizzini G, Conaldi PG. Direct-acting antivirals ability to clear intestinal HCV-RNA in liver transplant patients. *Transpl Infect Dis* 2020.
115. Mazzaferro V, Citterio D, Bhoori S, Bongini M, Miceli R, De Carlis L, Colledan M, Salizzoni M, Romagnoli R, Antonelli B, Vivarelli M, Tisone G, Rossi M, Gruttadauria S, Di Sandro S, De Carlis R, Lucà MG, De Giorgio M, Mirabella S, Belli L, Faggioli S, Martini S, Iavarone M, Svegliati Baroni G, Angelico M, Ginanni Corradini S, *Volpes R*, Mariani L, Regalia E, Flores M, Droz dit Busset Sposito C. Liver transplantation in hepatocellular carcinoma after tumour downstaging: a randomised, controlled, phase 2/3 trial. *Lancet Oncology* 2020.
116. Cannataci C, Miraglia R, Maruzzelli L, Petridis I, Tuzzolino F, *Volpes R*, Luca A. Single-centre mid-term experience using a new controlled-expansion e-PTFE covered stent for TIPS creation. *Clin Gastroenterol Hepatol* 2020.

117. Lo Re V, Maccora S, Smorlesi G, *Volpes R*, Sparacia G, Marrone G, Gruttadauria S, Luca A. Acute and reversible Pisa Syndrome as unusual presentation of portosystemic encephalopathy. *J Neurol Sci* 2020.
118. *Volpes R*, Burra P, Germani G, Manini MA, Caccamo L, Strignano P, Rizza G, Tamè M, Pinna AD, Calise F, Migliaccio C, Carrai P, De Simone P, Valentini MF, Lupo LG, Cordone G, Picciotto FP, Nicolucci A¹. Effect of switch from intravenous or intramuscular to subcutaneous hepatitis B immunoglobulin on quality of life after liver transplantation. *Health and Quality of Life Outcomes* 2020: 1-7
119. Martucci G, *Volpes R*, Panarello G, Tuzzolino F, Di Carlo D, Ricotta C, Gruttadauria S, Conaldi PG, Luca A, Amrein K, Arcadipane A. Vitamin D Levels in Liver Transplantation Recipients and Early Postoperative Outcomes: Prospective Observational DLiverX Study. *Clinical Nutrition* 2020.
120. D'Amico G, Perricone G, Morabito A, Latteri F, Filì D, Affronti A, Pietrosi G, Maida M, Rizzo GE, Bronte F, Petridis I, Bavetta MG, *Volpes R*, Malizia G, Luca A. Model for end stage liver disease for prediction of mortality in people with cirrhosis (Protocol). *Cochrane Database of Systematic Reviews* 2020, Issue 11. Art. No.: 8.
121. Cillo U, De Carlis L, Del Gaudio M, De Simone P, Faggioli S, Lupo F, Tisone G, *Volpes R*. Immunosuppressive regimens for adult liver transplant recipients in real-life practice: consensus recommendations from an Italian Working Group. *Hepatology International* 2020.
122. Duvoux C, Belli L, Fung J, Angelico M, Buti M, Coilly A, Cortesi P, Durand F, Féray C, Fondevila C, Lebray P, Martini S, Nevens F, Polak WG, Rizzetto M, *Volpes R*, Zoulim F, Samuel D, Berenguer M. 2020 Position Statement and Recommendations of the European Liver and Intestine Transplantation Association (ELITA): Management of Hepatitis B virus-related infection before and after liver transplantation. *Aliment Pharmacol & Ther*, 2021.
123. Belli L, Duvoux C, Artzner T, Bernal W, Conti S, Cortesi PA, Sacleux SC, Pageaux GP, Radenne S, Trebicka J, Fernandez J, Perricone G, Piano S, Nadalin S, Morelli MC, Martini S, Polac W, Zieniewicz K, Toso C, Berenguer M, Iegri C, Invernizzi F, *Volpes R*, Karam V, Faitot F, Rabinovich L, Saliba F, Meunier L, Lesurtel M, Uschner FE, Fondevila C, Michard B, Coilly A, Meszaros M, Poinot D, Schnitzbauer A, De Carlis LG, Fumagalli R, Angeli P, Arroyo V, Jalan R. Liver transplantation for patients with acute-on-chronic liver failure in Europe: Results of the ELITA/EF-CLIF Study (ECLIS). *J Hepatol* 2021.
124. D'Amico G, Perricone G, Morabito A, Latteri F, Filì D, Affronti A, Pietrosi G, Maida M, Rizzo GE, Bronte F, Petridis I, Bavetta MG, *Volpes R*, Malizia G, Luca A. Performance of the Model for End stage Liver Disease (MELD) for mortality prediction and potential role of etiology. *J Hepatol* 2022.
125. Burra P, Vitale A, Trapani S, Di Renzo C, Romagnoli R, Martini S, De Simone P, Carrai P, Cescon M, Morelli MC, De Carlis L, Belli L, Gruttadauria S, *Volpes R*, Colledan M, Faggioli S, Di Benedetto F, De Maria N, Rossi G, Donato F, Vennarecci G, Di Costanzo GG, Vivarelli M, Svegliati Baroni G, Carraro A, Colecchia A, Ettorre GM, Giannelli V, Agnes S, Grieco A, Rossi M, Ginanni Corradini S, Mazzaferro V, Bhoori S, Manzia TM, Lenci I, Zamboni F, Mameli L, Baccarani U, Toniutto PL, Lupo GL, Rendina M, Andorno E, Giannini EG, Spada M, Miele L, Dalla Riva GV, Marchesini Reggiani G, Ricci A, Cardillo M, Cillo U. The survival benefit of liver transplantation for nonalcoholic steatohepatitis: an Italian liver transplant registry study. *J Hepatol* 2022.

126. Antonelli B, Avolio A, Boccagni P, Bongini MA, Carraro A, Castellaneta A, Cescon M, Cillo U, De Carlis L, De Simone P, Del Gaudio M, Faggioli S, Galeota Ianza A, Guglielmo N, Guizzetti M, Lauterio A, Lorenzin D, Lupo F, Magistri P, Mameil L, Marengo S, Mirabella S, Nicolini D, Petridis I, Tisone G, Toniutto PL, Vennarecci G, Violi P, Volpes R. Linee di gestione per l'immunosoppressione nel paziente adulto trapiantato di fegato. Aggiornamento 2022. *Therapy Perspectives* 2022, 1: 1-36.
127. Cortesi PA, Viganò R, Conti S, Lenco I, Volpes R, Martini S, Angelico M, Fung J, Buti M, Coilly A, Durand F, Fondevila C, Lebray P, Nevens F, Polak WG, Rizzetto M, Zoulim F, Perricone G, Berenguer M, Mantovani LG, Duvoux C, Belli LS. Economical impact of European Liver and Intestine Transplantation Association (ELITA) recommendations for Hepatitis B prophylaxis after liver transplantation. *Transpl Intern* 2023; 36:1-7.

Publicazioni come "abstracts" (a Congressi Internazionali)

1. Craxì A, Volpes R, Di Marco V, Bruno R. Infezione cronica da virus dell'epatite non A, non B in pazienti talassemici: prospettive terapeutiche. *Ematologia '88*. 2° meeting internazionale. Ustica, Giugno 1988.
2. Volpes R, van den Oord JJ, Desmet VJ. Distribution of thrombospondin receptor in chronic HBV-infection. *J Hepatol* 1989; 9 (suppl 1):S93.
3. Volpes R, van den Oord JJ, Desmet VJ. Distribution of Intercellular Adhesion Molecule-1 (ICAM-1) in inflammatory liver disease. *J Hepatol* 1989, 9 (suppl 1):S93.
4. Volpes R, van den Oord JJ, Desmet VJ. Expression of a B-cell growth factor receptor (CDw40) on hepatocytes in areas of inflammation. *J Hepatol* 1989; 9 (suppl 1):S243.
5. Volpes R, van den Oord JJ, Desmet VJ. Distribution of Intercellular Adhesion Molecule-1 (ICAM-1) in chronic hepatitis B virus (HBV) infection. *Falk Symposium N.54. Infectious Diseases of the Liver*. Basel, October 1989; 252.
6. Volpes R, van den Oord JJ, Desmet VJ. Distribution of Intercellular Adhesion Molecule-1 (ICAM-1) in chronic hepatitis B virus (HBV) infection. *Hepatology* 1989; 10:582.
7. Di Marco V, Bruno R, Volpes R. Interferon linfoblastoide a breve e lungo termine nelle epatiti croniche non A, non B. XXVII Congresso nazionale della Società Italiana di Gastroenterologia (SIGE). Bologna, dicembre 1989; 511-514.

8. Craxì A, Volpes R, Di Marco V. Alfa-interferon treatment of chronic HDV hepatitis in children. International Symposium on "La terapia delle Malattie Epatiche". Milano, febbraio 1989; 16.
9. Craxì A, Volpes R, Di Marco V, Bruno R, Palazzo U. Alfa-interferon treatment of posttransfusion non A, non B hepatitis: effectiveness in patients with single and multiple exposure. International Symposium on "La terapia delle Malattie Epatiche". Milano, Febbraio 1989; 39.
10. Craxì A, Volpes R, Di Marco V. Alfa-interferon treatment of chronic HDV hepatitis in children. Third International Symposium on Hepatitis Delta Virus. Washington, October 1989.
11. Craxì A, Volpes R, Di Marco V. Treatment with Interferon Alfa-2b of chronic HDV hepatitis in children. International Meeting on Management of chronic viral hepatitis. Montecarlo, Dicembre 1989.
12. Volpes R, van den Oord JJ, De Vos R, Depla E, De Ley M, Desmet VJ. Expression of interferon-gamma receptor in normal and pathological HBV-infected human liver tissue. AASLD Single Topic Conference. Immunology and the Liver. Washington, March-April 1990; 25.
13. Volpes R, van den Oord JJ, Desmet VJ. Distribution of the thrombospondin-receptor in HBV+ inflammatory liver disease. The 7th Triennial International Congress on Viral Hepatitis and Liver Disease. Houston, April 1990; 72:118.
14. Volpes R, van den Oord JJ, Desmet VJ. Coexpression of Intercellular Adhesion Molecule1 (ICAM-1) and HLA-DR antigens by hepatocytes in HBV+ inflammatory liver diseases. The 7th Triennial International Congress on Viral Hepatitis and Liver Disease. Houston, April 1990; 72:119.
15. Volpes R, van den Oord JJ, Desmet VJ. Two adhesion pathways of T-cell/hepatocyte interaction in HBV+ inflammatory liver disease. The 7th Triennial International Congress on Viral Hepatitis and Liver Disease. Houston, April 1990; 72:120.
16. Volpes R, van den Oord JJ, De Vos R, Depla E, De Ley M, Desmet VJ. Expression of interferon-gamma receptor in normal and pathological HBV-infected human liver tissue. J Hepatol 1990; 11 (suppl 2):S64.
17. Volpes R, van den Oord JJ, Desmet VJ. Expression of VLA adhesion molecules in normal and pathological human liver tissue. J Hepatol 1990; 11 (suppl 2):S65.
18. van den Oord JJ, Volpes R, Desmet VJ. Intrahepatic T-cells in chronic HBV-infection, and their effect on the phenotype of near-by hepatocytes. Sixth International Congress of Mucosal Immunology. Tokyo, July 1990; 223.
19. Volpes R, van den Oord JJ, Desmet VJ. Homing of T-lymphocytes in acute and chronic HBV+ inflammatory liver disease. Current trends in chronically-evolving viral hepatitis. Siena, October 1990; 72.
20. Lauweryns B, van den Oord JJ, Volpes R, Foets B, Missotten L. Immunohistochemical study of VLA-integrins in human cornea. 31st Meeting of the Association of Eye Research. Bonn, October 1990.

21. Volpes R, van den Oord JJ, Desmet VJ. Memory T-cells predominate in acute and in chronic HBV-related liver diseases. *Hepatology* 1990; 12:905.
22. Volpes R, van den Oord JJ, Desmet VJ. Endothelial adhesion molecules in acute and chronic inflammatory liver diseases. *Hepatology* 1990; 12:910.
23. Volpes R, Yap S-H, van den Oord JJ, Acs G, Desmet VJ. Induction of Intercellular Adhesion Molecule-1 (ICAM-1) on HepG2 cells: influence of cytokines and HBV-DNA transfection. *Hepatology* 1990; 12:921.
24. Volpes R, van den Oord JJ, Desmet VJ. Distribution of VLA adhesion molecules in normal and pathological liver tissue. *Hepatology* 1990; 12:954.
25. Volpes R, van den Oord JJ, Desmet VJ. Hepatocytes express the vitronectin receptor in inflammatory and cholestatic liver disease. *J Hepatol* 1991; 13 (suppl.2):S79.
26. Volpes R, van den Oord JJ, Desmet VJ. Hepatocytes express receptors for cytokines and acquire an "activated" phenotype in inflammatory liver diseases. *J Hepatol* 1991; 13 (suppl.2):S180.
27. Volpes R, van den Oord JJ, Desmet VJ. Integrins as lineage markers of primary hepatic neoplasms. *Hepatology* 1991; 14:109A.
28. Volpes R. Intrahepatic expression of accessory molecules in HBV-mediated pathology. Abstract Book. International Meeting on "Biology, Immunopathology and Clinic of Hepatitis viruses. From infection to disease". Parma, June 1993; 32-33.
29. Volpes R, Almasio P, Di Marco V, Lo Iacono O, Pagliaro L, Craxì A. Lymphoid follicles and Hepatitis C Virus replication: effects of interferon treatment. *Hepatology* 1994; 19:1391.
30. Volpes R, Almasio P, Di Marco V, Lo Iacono O, Craxì A, Pagliaro L. Lymphoid follicles and Hepatitis C Virus replication: effects of interferon treatment. *It J Gastroenterol* 1995; 27:334.
31. David E, Zamboni F, Volpes R, Lupo F, Delsedime L, Rocca G, Papandrea C, Andorno E, Rizzetto M, Salizzoni M. Histological findings of donor liver biopsies as prognostic indicators of graft function. *It J Gastroenterol* 1995; 27 (suppl 1):82.
32. David E, Zamboni F, Volpes R, Lupo F, Magnani C, Bo P, Dinolfo L, Delsedime L, Andorno E, Rizzetto M, Salizzoni M. The role of histopathology in the differential diagnosis of bacterial cholangitis, cellular rejection and recurrence of HCV hepatitis after orthotopic liver transplantation. *It J Gastroenterol* 1995; 27 (suppl 1):83.
33. Lavezzo B, Lupo F, David E, Ghisetti V, Durazzo M, Ottobrelli A, Zamboni F, Volpes R, Smedile A, Salizzoni M, Verme G, Rizzetto M. Factors associated with cholestatic hepatitis after liver transplantation for cirrhosis type C (HCV). *It J Gastroenterol* 1995; 27 (suppl 1):144.
34. Caronia S, D'Amico G, Caltagirone M, Palazzo U, Sciarrino E, Bruno R, Simone F, Pagliaro L, Lavezzo B, Smedile A, Volpes R, Rizzetto M. Recurrence of acute and chronic hepatitis in patients undergoing OLT for HCV related cirrhosis. *It J Gastroenterol* 1995; 27:461.

35. David E, Volpes R, Zamboni F, Delsedime L, Andorno E, Lupo F, Magnani C, Bo P, Dinolfo L, Verme G, Salizzoni M, Rizzetto M. Bacterial cholangitis after liver transplantation: morphological features and differential diagnosis. *It J Gastroenterol* 1995; 27:463.
36. David E, Volpes R, Zamboni F, Lupo F, Rocca G, Delsedime L, Bo P, Dinolfo L, Andorno E, Verme G, Salizzoni M, Rizzetto M. Predictive value of donor liver biopsies on early graft function after orthotopic liver transplantation. *It J Gastroenterol* 1995; 27:464.
37. Lavezzo B, Smedile A, David E, Ghisetti V, Durazzo M, Ottobrelli A, Volpes R, Zamboni F, Lupo F, Salizzoni M, Verme G, Rizzetto M. Factors associated with cholestatic hepatitis after liver transplantation for cirrhosis type C (HCV). *It J Gastroenterol* 1995; 27:467.
38. Rocca G, David E, Zamboni F, Volpes R, Delsedime L, Smedile A, Lavezzo B, Bellis D, Bo P, Dinolfo L, Lupo F, Salizzoni M, Rizzetto M. Ductopenic rejection and underlying liver disease indications to orthotopic liver transplantation. The 9th Triennial International Symposium on Viral Hepatitis and Liver Disease. Roma, April 1996; 350:288.
39. David E, Rocca G, Volpes R, Delsedime L, Zamboni F, Andorno E, Bo P, Dinolfo L, Bernardi P, Perron Cabus G, Porelli P, Salizzoni M, Rizzetto M. Cellular rejection, bacterial cholangitis and recurrence of hepatitis C in liver transplant: a clinical-histological assessment. The 9th Triennial International Symposium on Viral Hepatitis and Liver Disease. Roma, April 1996; 350:289.
40. Volpes R, Rocca G, David E, Zamboni F, Salizzoni M, Rizzetto M. Ductopenic rejection and underlying liver disease indications to orthotopic liver transplantation. Evidence for a correlation with Hepatitis C Virus infection. International Falk Symposium on "Vanishing Bile Duct Syndrome - Pathophysiology and Treatment". Spoleto, May-June 1996.
41. Volpes R, Rocca G, David E, Zamboni F, Salizzoni M, Rizzetto M. Ductopenic rejection and underlying liver disease indications to orthotopic liver transplantation. Evidence for a correlation with Hepatitis C Virus infection. A Symposium in honour of Prof. V.J. Desmet. Leuven, October 1996.
42. Oliveri F, Maina AM, Aimo G, Volpes R, David E, Zaccaria R, Pagni R, Brunetto MR, Bonino F. Use of serum markers of fibrogenesis in the assessment of liver fibrosis in chronic liver disease. *J Hepatol* 1997; 26:274.
43. Tassopoulos NC, Volpes R, Pastore G, Heathcote J, Buti M, Goldin RD, Hawley S, Gray DF. Lamivudine treatment in patients with HBeAg negative chronic hepatitis B: end of treatment analysis. *J Hepatol* 1998; 28:43.
44. Ciancio A, Rocca G, Smedile A, David E, Lagget M, Ottobrelli A, Marzano A, Torrani M, Volpes R, Salizzoni M, Rizzetto M. Prognosis of transplanted cirrhotic patients with hepatocellular carcinoma. *J Hepatol* 1999; 30:216.
45. Tassopoulos NC, Volpes R, Pastore G, Heathcote J, Buti M, Goldin RD, Hawley S, Barber J, Condreay L, Gray DF. Post-lamivudine treatment follow-up of patients with HBeAg negative/HBV-DNA positive chronic hepatitis B. *J Hepatol* 1999; 30:117.

46. Volpes R, Actis GC, Caronna S, Rizzetto M. Safety of azathioprine in patients with severe inflammatory bowel disease. Proceedings of Falk Symposium N.111. "IBD at the end of its first century". Freiburg, June 1999; 60.
47. Volpes R, Actis GC, Caronna S, Rizzetto M. Rapid steroid sparing in steroid-dependent chronic active ulcerative colitis patients: a novel indication for oral microemulsion cyclosporin (Neoral). Proceedings of Falk Symposium N.111. "IBD at the end of its first century". Freiburg, June 1999; 44.
48. Pinna-Pintor M, Actis GC, Volpes R, Rizzetto M. Outcome of restorative proctocolectomy in ulcerative colitis patients previously treated with cyclosporin. Proceedings of Falk Symposium N.111. "IBD at the end of its first century". Freiburg, June 1999; 43.
49. Actis GC, Volpes R, Aimo G, Priolo G, Moscato D, Rizzetto M, Pagni R. Cyclosporin for corticosteroid-refractory ulcerative colitis. Refinement of current treatment modalities. Proceedings of Falk Symposium N.111, "IBD at the end of its first century". Freiburg, June 1999; 54.
50. Cutrin JC, Zingaro B, Volpes R. Ischemic preconditioning protects the rat liver to oxidative stress damage and neutrophil infiltration. *Hepatology* 1999; 30:227A.
51. Luca A, Vizzini G, Miraglia R, Brancatelli G, Palazzo U, Volpes R, Renda P, Gruttadauria S, Doria C, Marino IR. Predictive factors of massive tumor necrosis induced by transcatheter arterial treatment in patients with hepatocellular carcinoma. *Hepatology* 2002; 36:685A.
52. Vizzini GB, Mandalà L, Kadry Z, Volpes R, D'Antoni A, Pietrosi G, Luca A, Gelsomino S, Arcadipane A, Gridelli B. Adjusted MELD scheme for hepatocellular carcinoma (HCC) does not reflect actual risk of death and drop-out in patients in waiting list for liver transplantation (OLT). *Liver Transpl* 2004; 10:C52.
53. Montalbano M, De Caro G, Volpes R, Minervini MI, Gridelli B. Transplantation of HBsAg-positive livers: a suitable option for all HBV positive recipients? A single center experience. *J Hepatol* 2006; 44:S64.
54. Lamonaca V, Di Stefano R, Caruana G, Volpes R, Campanella M, Vizzini G, Grossi P, Gridelli B. Effect of nose carrier screening in liver transplant candidates for preventing staphylococcus aureus infections after transplantation: a retrospective study. *Liver Transpl* 2006, 12: C21.
55. Tarantino I, Traina M, Barresi L, Di Pisa M, Volpes R, Gridelli B. Endoscopic treatment for biliary complications after liver transplantation. *Liver Transpl* 2006, 12: C25.
56. Gruttadauria S, Mandalà L, Cintorino D, Pietrosi G, Doffria E, Musumeci A, Verزارo D, Spada M, Volpes R, Vizzini G, Palazzo U, Arcadipane A, Burgio G, Castellese M, Marsh WJ, Marcos A, Gridelli B. Thirty cases of adult-to-adult living related liver transplantation: single-center experience in Italy. *Liver Transpl* 2006, 12: C64.
57. Volpes R, Gruttadauria S, Wallis Marsh J, Vizzini G, Palazzo U, Marcos A, Gridelli B. Living donor liver transplantation in adults: a single-center experience in Italy. *Dig Liv Dis* 2007; 39:A8.

58. Gruttadauria S, Mandala' L, Petridis I, Luna E, Miraglia R, Caruso S, Vizzini G, Volpes R, Wallis Marsh J, Luca A, Marcos A, Gridelli B. Role of splenic artery embolization in the treatment of small for size syndrome in Adult to Adult Living Related Liver Transplantation. *HPB* 2007; 9:34.
59. Petridis I, Gruttadauria S, Nadalin S, Pietrosi G, Filì D, Montalbano M, D'Antoni A, Volpes R, Vizzini G, Gridelli B. Liver Transplantation Using Donors Older Than 80: A Single Center Experience. *Dig Liv Dis* 2007; 39:A66..
60. Volpes R. Living donor liver transplantation in Italy. Impact on waiting list. *Dig Liv Dis* 2007.
61. Randisi L, Volpes R, Gruttadauria S, Castellese M, Rubino M, Minervini M, Vizzini G, Gridelli B. Usage of donor steatotic livers after a short-term intensive dietary treatment in living donor transplantation in adults. *Dig Liv Dis* 2007; 39:A45.
62. Pietrosi G, Fili' D, Vizzini G, Lamonaca V, Panarello G, Minervini M, Conaldi PG, Volpes R, D'Antoni A, Montalbano M, Petridis I, Gridelli B. Human Herpesvirus 8 Infection (HHV-8) in Liver Transplant (LT) recipients: an emergent fatal complication in southern Italy. *Dig Liv Dis* 2007; 39:A33.
63. Volpes R, Randisi L, Gruttadauria S, Castellese M, Rubino M, Minervini M, Vizzini G, Gridelli B. Usage of donors with steatosis after an intensive dietary treatment in living donor transplantation in adults. *Hepatology* 2007.
64. Pietrosi G, Fili' D, Vizzini G, Lamonaca V, Panarello G, Minervini M, Conaldi PG, Volpes R, D'Antoni A, Montalbano M, Petridis I, Gridelli B. Human Herpesvirus 8 Infection (HHV-8) in Liver Transplant (LT) recipients: an emergent fatal complication in southern Italy. *Hepatology* 2007.
65. Filì D, Vizzini G, Biondo D, Volpes R, Pietrosi G, D'Antoni A, Montalbano M, Petridis I, Luca A, Scardulla C, Hernandez-Baravoglia C, Gridelli B. Coronary artery disease screening in liver transplant candidates. *Hepatology* 2007.
66. Burra P, Andreone P, Volpes R, Canova D, Cursaro C, Riili A, Fiornetino B, Bacci M, Guazzini S, Marzano A. Pharmacokinetics, efficacy and safety of human hepatitis B immunoglobulin for intravenous and intramuscular use in prophylaxis of hepatitis B after liver transplantation. *Transpl Int* 2007; 20:36.
67. Volpes R, Gruttadauria S, Wallis Marsh J, Vizzini G, Palazzo U, Marcos A, Gridelli B. Living donor liver transplantation in adults: a single-center experience in Italy. *Transpl Int* 2007; 20:257.
68. Gruttadauria S, Scianna G, Cintonino D, Luca A, Palazzo U, Arcadipane A, Volpes R, Vizzini G, Gridelli B. Living related liver transplantation: a resource to increase the donor pool. *Transpl Int* 2007; 20:333.
69. Marzano A, Andreone P, Volpes R, Canova D, Cursaro C, Riili A, Fiorentino B, Bacci M, Guazzini S, Burra P. Pharmacokinetics, efficacy and safety of intramuscular and intravenous hepatitis B immunoglobulins combined with nucleoside analogues in prophylaxis of hepatitis B after liver transplantation. *J Hep* 2008; 48:S261.

70. Randisi L, Rubino M, Volpes R, Gruttadauria S, Castellese M, Vizzini G, Minervini M, Gridelli B. Short-term intensive dietary treatment for a safe usage of steatotic donors in living donor transplantation. *Clin Nutr* 2008; 3 (suppl 1):87.
71. Volpes R, Burra P, Andreone P, Canova D, Cursaro C, Riili A, Bacci M, Fiorentino B, Guazzini S, Marzano A. Pharmacokinetics, efficacy and safety of intramuscular and intravenous hepatitis B immunoglobulins combined with nucleoside analogues in prophylaxis of hepatitis B after liver transplantation. *Liv Transpl* 2008; 14: (suppl 1), S182.
72. Petridis I, Tarantino I, Barresi, Traina M, Volpes R, Gruttadauria S, Marsh J, Vizzini G, Palazzo U, Marcos A, Gridelli B. Diagnosis and treatment of biliary complications after liver transplantation: the ISMETT-UPMC experience. *GUT* 2008; 57: (suppl II), A207.
73. Tarantino I, Traina M, Barresi L, Petridis I, Volpes R, Gridelli B. Full covered metal biliary stents for treatment of biliary complications after liver transplantation. *Dig Liv Dis* 2009; 41S:S10.
74. Traina M, Volpes R, Tarantino I, Petridis I, Barresi L, Gridelli B. Full covered metal biliary stents for treatment of biliary complications after liver transplantation. *Digestive Disease Week®*, Chicago, IL, May 30 - June 4, 2009.
75. Belli L, Volpes R, Graziadei I, Starkel P, Burroughs AK, Burra P, Fagiuoli S, Alberti A, Guido M, Pasulo L, Vogel W, Gridelli B, Cillo U, De Carlis L, Pinzello G. Peg-IFN-alfa2b with ribavirin for the prevention of histological fibrosis progression in patients with HCV hepatitis recurrence. A multicenter randomized controlled study. Interim report. *Transpl Int* 2009; S2:27-28.
76. Petridis I, Gruttadauria S, D'Antoni A, Volpes R, Vizzini G, Gridelli B. Extended criteria donor liver grafts are the answer for expanding the liver donor pool: results of a single Center. *Ann Gastroenterol* 2009; 22:57.
77. Belli L, Volpes R, Graziadei I, Starkel P, Burroughs AK, Burra P, Fagiuoli S, Alberti A, Guido M, Pasulo L, Vogel W, Gridelli B, Cillo U, De Carlis L, Pinzello G. Peg-IFN-alfa2b with ribavirin for the prevention of histological fibrosis progression in patients with HCV hepatitis recurrence. A multicenter randomized controlled study. *Hepatology* 2009; 98:A.
78. Petridis I, Miraglia R, Gruttadauria S, Pagano D, Volpes R, Luca A, Vizzini G, Palazzo U, Gridelli B. Portal hypertension after liver transplantation. *Liver Transpl* 2010; 16:S109110.
79. Burra P, Caccamo L, Volpes R, Ercolani G, Scuderi V, Pacilio R, Magni B, Boccagni P, Strignano P, Cibelli A, De Martin E, Lazzaro S, Calise F, Pinna A, Rossi G, Di Costanzo G, Carrai P, Cillo U, Salizzoni M, Franciosi M, Nicolucci A. Development and validation of an instrument evaluating the impact of anti HBV Immunoglobulin therapy (HBIG) on quality of life (HRQOL) in liver transplant (LT) patients. *Transpl Int* 2011; 24 (S2):168.
80. Petridis I, Miraglia R, Gruttadauria S, Volpes R, Luca A, Vizzini G, Palazzo U, Gridelli B. Risk factors for HCC recurrence after liver transplantation. *Ann Gastroenterol* 2011; 24:S24.

81. Volpes R, Galatioto L, Vizzini G, Gridelli B. Efficacy and feasibility of conversion to subcutaneous (SC) human HBV-immunoglobulins (HBIG) for the prophylaxis of HBV recurrence after liver transplantation. *J Hepatol* 2011.
82. Volpes R, Galatioto L, Vizzini G, Gridelli B. "Early conversion to subcutaneous (SC) human HBV-Immunglobulins (HBIG) is safe and effective in preventing HBV recurrence after liver transplantation. *Liv Transpl* 2012; 18:S126.
83. Caccamo L, Franciosi M, De Simone P, Pinna A, Di Costanzo G, Volpes R, Scuderi V, Strignano P, Boccagni P, Burra P, Nicolucci A. Impact of anti-HBV Immunoglobulins on quality of life after liver transplantation. *Liv Transpl* 2012; 18:S175.
84. Calvaruso V, Cacciola I, Russello M, Davì A, Scifo G, Volpes R, Montineri A, Prestileo T, Madonia S, Malizia G, Digiacomo A, Bertino G, Magro A, Licata A, Cacopardo B, Salvo A, Guarneri L, Scalisi I, Mannino G, Colletti P, Cartabellotta F, Portelli V, Raimondo G, Craxì A, Di Marco V (on behalf of RESIST-HCV (Rete Sicilia Selezione Terapia – HCV). Treatment of elderly HCV patients with severe fibrosis: safety and efficacy data from RESIST-HCV, a large regional database. *Hepatology* 2016; 64:474A.
85. Madonia S, Calvaruso V, Cacciola I, Russello M, Davì A, Scifo G, Volpes R, Montineri A, Prestileo T, Malizia G, Digiacomo A, Bertino G, Magro A, Licata A, Cacopardo B, Salvo A, Guarneri L, Scalisi I, Mannino G, Colletti P, Cartabellotta F, Portelli V, Canizzaro M, Raimondo G, Craxì A, Di Marco V (on behalf of RESIST-HCV (Rete Sicilia Selezione Terapia – HCV). Efficacy and safety of DAA regimens in HCV genotype 1b patients with compensated cirrhosis: data of RESIST-HCV Cohort. *Hepatology* 2016; 64:1930A.
86. Belli L, Berenguer M, Cortesi P, Facchetti R, Strazzabosco M, Perricone G, Rockenschaub S, Martini S, Morelli C, Donato MF, Volpes R, Pageaug GP, Coilly A, Fagioli S, Berlakovich G, Monico S, Vinaixa C, Polak W, Duvoux C and European Liver and Intestine Association (ELITA). Delisting of liver transplant candidates with chronic hepatitis C virus infection after viral eradication: outcome after delisting: a European study. *J Hepatol* 2017, 66:S39.
87. Calvaruso V, Cacciola I, Licata A, Madonia S, Benigno R, Bronte F, Petta S, Malizia G, Bertino G, Di Stefano M, Volpes R, Montineri A, Digiacomo A, Alaimo G, Cacopardo B, Guarneri L, Scalisi I, Mazzola G, Cartabellotta F, Portelli V, Russello M, Squadrito G, Raimondo G, Craxì A, Di Marco V on behalf of RESIST-HCV (Rete Sicilia Selezione Terapia – HCV). Non-invasive tools to ruling out large varices: RESIST-HCV vs Baveno VI criteria in a large cohort of patients with HCV cirrhosis. *J Hepatol* 2017, 66:S563.
88. Cacciola I, Petta S, Di Stefano M, Cannavò MR, Davì A, Madonia S, Calvaruso V, La Rocca L, Di Lorenzo F, Digiacomo A, Bertino G, Licata A, Benanti F, Volpes R, Guarneri L, Averna A, Scalisi I, Iacobello C, Colletti P, Cartabellotta F, Portelli V, Russello M, Scifo G, Squadrito G, Raimondo G, Craxì A, Di Marco V on behalf of RESIST-HCV (Rete Sicilia Selezione Terapia – HCV). Efficacy of oral Direct Acting Antivirals for the treatment of chronic hepatitis/cirrhosis due to hepatitis C virus infection: the real-life experience of the Sicily Registry. *J Hepatol* 2017, 66:S510.
89. Madonia S, Calvaruso V, Filomia R, Cannavò MR, Di Stefano M, Russello M, Davì A, Scifo G, Volpes R, Montineri A, Ficalora R, Malizia G, Digiacomo A, Bertino G, Alaimo G, Licata A, Cacopardo B, Averna A, Guarneri L, Scalisi I, Colletti P, Cartabellotta F, Savalli F, Cannizzaro M, Raimondo G, Craxì A, Di Marco V on behalf of RESIST-HCV (Rete Sicilia

Selezione Terapia – HCV). Efficacy and safety of 12-week DAA regimens in HCV genotype 1b patients with compensated cirrhosis: data of RESIST-HCV Cohort. *J Hepatol* 2017, 66:S735.

90. Cabibbo G, Cacciola I, Cannavò MR, Madonia S, Calvaruso V, Petta S, Di Stefano M, La Rocca L, Prestileo T, Tinè F, Digiacomo A, Bertino G, Giannitrapani L, Benanti F, Davì A, Volpes R, Guarneri L, Averna A, Scalisi I, Iacobello C, Mazzola G, Cartabellotta F, Portelli V, Russello M, Scifo G, Squadrito G, Raimondo G, Craxì A, Di Marco V, Cammà C on behalf of RESIST-HCV (Rete Sicilia Selezione Terapia – HCV). Risk of Hepatocellular Carcinoma (HCC) Recurrence in HCV cirrhotic patients treated with direct acting antivirals (DAAs). *J Hepatol* 2017, 66:S218.
91. Petridis I, Volpes R, D'Antoni A, Pietrosi G, Maruzzelli L, Miraglia R, Luca A. A novel TIPS-controlled expansion stent for the treatment of severe portal hypertension. A single center experience. *Hepatology* 2017; 66:1771.

Presentazioni a Convegni Internazionali

1. Volpes R, van den Oord JJ, Desmet VJ. Distribution of Intercellular Adhesion Molecule-1 (ICAM-1) in inflammatory liver disease. 24th Meeting of the European Association for the Study of the Liver (EASL). Munich, August-September 1989.
2. Volpes R, van den Oord JJ, Desmet VJ. Distribution of Intercellular Adhesion Molecule-1 (ICAM-1) in chronic hepatitis B virus (HBV) infection. 8th International Congress of Liver Diseases. Infectious Diseases of the Liver. Falk Symposium N. 54. Basel, October 1989.
3. Volpes R, van den Oord JJ, Desmet VJ. Distribution of Intercellular Adhesion Molecule-1 (ICAM-1) in chronic hepatitis B virus (HBV) infection. 40th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). Chicago, October/November 1989.
4. Volpes R, van den Oord JJ, De Vos R, Depla E, De Ley M, Desmet VJ. Expression of interferon-gamma receptor in normal and pathological HBV-infected liver tissue. American Association for the Study of the Liver Diseases (AASLD) Single Topic Conference. Immunology and the Liver. Washington, March-April 1990.
5. Volpes R, van den Oord JJ, Desmet VJ. Distribution of the thrombospondin receptor in HBV+ inflammatory liver disease. 7th Triennial International Congress on Viral Hepatitis and Liver Disease. Houston, April 1990.
6. Volpes R, van den Oord JJ, Desmet VJ. Coexpression of Intercellular Adhesion Molecule-1 (ICAM-1) and HLA-DR antigens by hepatocytes in HBV+ inflammatory liver disease. 7th Triennial International Congress on Viral Hepatitis and Liver Disease. Houston, April 1990.
7. Volpes R, van den Oord JJ, Desmet VJ. Two adhesion pathways of T-cell/hepatocyte interaction in HBV+ inflammatory liver disease. 7th Triennial International Congress on Viral Hepatitis and Liver Disease. Houston, April 1990.
8. van den Oord JJ, Volpes R, Desmet VJ. Intrahepatic T-cells in chronic HBV-infection, and their effect on the phenotype of near-by hepatocytes. 6th International Congress of Mucosal Immunology. Tokyo, July 1990.
9. Lauweryns B, van den Oord JJ, Volpes R, Foets B, Missotten L. Immunohistochemical study of VLA-Integrins in human cornea. 31st Meeting of the Association of Eye Research. Bonn, October 1990.
10. Volpes R, van den Oord JJ, De Vos R, Depla E, De Ley M, Desmet VJ. Expression of interferon-gamma receptors in normal and pathological human liver tissue. 25th Meeting of the European Association for the Study of the Liver (EASL). Budapest, October 1990.
11. Volpes R, van den Oord JJ, Desmet VJ. Expression of VLA adhesion molecules in normal and pathological human liver tissue. 25th Meeting of the European Association for the Study of the Liver (EASL). Budapest, October 1990.

12. Volpes R, van den Oord JJ, Desmet VJ. Lymphocyte homing in acute and chronic HBV-related liver disease. 2nd International Conference Current Trends in Chronicallyevolving Viral Hepatitis. Siena, October 1990.
13. Volpes R, van den Oord JJ, Desmet VJ. Memory T-cells predominate in acute and chronic HBV-related liver diseases. 41st Annual Meeting of the American Association for the Study of the Liver Diseases (AASLD). Chicago, November 1990.
14. Volpes R, van den Oord JJ, Desmet VJ. Endothelial adhesion molecules in acute and chronic inflammatory liver diseases. 41st Annual Meeting of the American Association for the Study of the Liver Diseases (AASLD). Chicago, November 1990.
15. Volpes R, Yap S-H, van den Oord JJ, Acs G, Desmet VJ. Induction of Intercellular Adhesion Molecule-1 (ICAM-1) on HepG2 cells: influence of cytokines and HBV-DNA transfection. 41st Annual Meeting of the American Association for the Study of the Liver Diseases (AASLD). Chicago, November 1990.
16. Volpes R, van den Oord JJ, Desmet VJ. Hepatocytes express the vitronectin receptor in inflammatory and cholestatic liver disease. 26th Meeting of the European Association for the Study of the Liver (EASL). Palma de Mallorca, September 1991.
17. Volpes R, van den Oord JJ, Desmet VJ. Integrins as lineage markers of primary hepatic neoplasms. 42nd Annual Meeting of the American Association for the Study of the Liver diseases (AASLD). Chicago, November 1991.
18. Volpes R. Intrahepatic expression of accessory molecules in HBV-mediated pathology. International Meeting on "Biology, Immunopathology and Clinic of Hepatitis viruses. From infection to disease". Parma, Giugno 1993.
19. Volpes R. Molecole di adesione immunitaria nelle malattie infiammatorie del fegato. Meeting on: "Epatiti ed autoimmunità". S. Giovanni Rotondo (FO), Gennaio 1994.
20. Volpes R. Molecole di adesione ed epatite virale cronica. Meeting on: "Epatite virale cronica. Dalla diagnosi alla terapia". Monopoli (BA), Aprile 1994.
21. Volpes R, Almasio P, Di Marco V, Lo Iacono O, Pagliaro L, Craxì A. Lymphoid follicles and Hepatitis C Virus replication: effects of interferon treatment. Biennal Scientific Meeting of the International Association for the Study of the Liver (IASL). Cancun, May 1994.
22. Volpes R. Grading and Staging of Chronic Hepatitis. International Congress on "Infectious Diseases 1995". Lecce, November 1995.
23. Rocca G, David E, Zamboni F, Volpes R, Delsedime L, Smedile A, Lavezzo B, Bellis D, Bo P, Dinolfo L, Lupo F, Salizzoni M, Rizzetto M. Ductopenic rejection and underlying liver disease indications to orthotopic liver transplantation. The 9th Triennial International Symposium on Viral Hepatitis and Liver Disease. Roma, April 1996.
24. David E, Rocca G, Volpes R, Delsedime L, Zamboni F, Andorno E, Bo P, Dinolfo L, Bernardi P, Perron Cabus G, Porelli P, Salizzoni M, Rizzetto M. Cellular rejection, bacterial cholangitis and recurrence of hepatitis C in liver transplant: a clinical-histological assessment. The 9th Triennial International Symposium on Viral Hepatitis and Liver Disease. Roma, April 1996.

25. Volpes R, Rocca G, David E, Zamboni F, Salizzoni M, Rizzetto M. Ductopenic rejection and underlying liver disease indication to orthotopic liver transplantation. Evidence for a correlation with Hepatitis C Virus infection. International Falk Symposium on "Vanishing Bile Duct Syndrome - Pathophysiology and Treatment". Spoleto, May-June 1996.
26. Volpes R, Rocca G, David E, Zamboni F, Salizzoni M, Rizzetto M. Ductopenic rejection and underlying liver disease indication to orthotopic liver transplantation. Evidence for a correlation with Hepatitis C Virus infection. A Symposium in honour of Prof. V.J. Desmet. Leuven, October 1996.
27. Tassopoulos NC, Volpes R, Pastore G, Heathcote J, Buti M, Goldin RD, Hawley S, Gray DF. Lamivudine treatment in patients with HBeAg negative chronic hepatitis B: end of treatment analysis. 33th Meeting of the European Association for the Study of the Liver (EASL). Lisbon, April 1998.
28. Tassopoulos NC, Volpes R, Pastore G, Heathcote J, Buti M, Goldin RD, Hawley S, Barber J, Condreay L, Gray DF. Post-lamivudine treatment follow-up of patients with HBeAg negative/HBV-DNA positive chronic hepatitis B. 34th Meeting of the European Association for the Study of the Liver (EASL). Naples, April 1999.
29. Volpes R, Actis GC, Caronna S, Rizzetto M. Safety of azathioprine in patients with severe inflammatory bowel disease. Falk Symposium N.111. "IBD at the end of its first century". Freiburg, June 1999.
30. Volpes R, Actis GC, Caronna S, Rizzetto M. Rapid steroid sparing in steroid-dependent chronic active ulcerative colitis patients: a novel indication for oral microemulsion cyclosporin (Neoral). Falk Symposium N.111. "IBD at the end of its first century". Freiburg, June 1999.
31. Pinna-Pintor M, Actis GC, Volpes R, Rizzetto M. Outcome of restorative proctocolectomy in ulcerative colitis patients previously treated with cyclosporin. Falk Symposium N.111. "IBD at the end of its first century". Freiburg, June 1999.
32. Actis GC, Volpes R, Aimo G, Priolo G, Moscato D, Rizzetto M, Pagni R. Cyclosporin for corticosteroid-refractory ulcerative colitis. Refinement of current treatment modalities. Proceedings of Falk Symposium N.111, "IBD at the end of its first century". Freiburg, June 1999.
33. Cutrin JC, Zingaro B, Volpes R. Ischemic preconditioning protects the rat liver to oxidative stress damage and neutrophil infiltration. 50th Annual Meeting of the American Association for the Study of the Liver diseases (AASLD). Dallas, November 1999.
34. Vizzini GB, Mandalà L, Kadry Z, Volpes R, D'Antoni A, Pietrosi G, Luca A, Gelsomino S, Arcadipane A, Gridelli B. Adjusted MELD scheme for hepatocellular carcinoma (HCC) does not reflect actual risk of death and drop-out in patients in waiting list for liver transplantation (OLT). International Liver Transplant Society and Licage. Kyoto, May 2004.

35. Montalbano M, De Caro G, Volpes R, Minervini MI, Gridelli B. Transplantation of HBsAg-positive livers: a suitable option for all HBV positive recipients? A single center experience. 41st Annual Meeting of the European Association for the Study of the Liver (EASL). Vienna, April 2006.
36. Lamonaca V, Di Stefano R, Caruana G, Volpes R, Campanella M, Vizzini G, Grossi P, Gridelli B. Effect of nose carrier screening in liver transplant candidates for preventing staphylococcus aureus infections after transplantation: a retrospective study. International Liver Transplant Society, ELTA and Licage. Milano, May 2006.
37. Tarantino I, Traina M, Barresi L, Di Pisa M, Volpes R, Gridelli B. Endoscopical treatment for biliary complications after liver transplantation. International Liver Transplant Society, ELTA and Licage. Milano, May 2006.
38. Gruttadauria S, Mandalà L, Cintorino D, Pietrosi G, Doffria E, Musumeci A, Verzaro D, Spada M, Volpes R, Vizzini G, Palazzo U, Arcadipane A, Burgio G, Castellese M, Marsch WJ, Marcos A, Gridelli B. Thirty cases of adult-to-adult living related liver transplantation: single-center experience in Italy. International Liver Transplant Society, ELTA and Licage. Milano, May 2006.
39. Gruttadauria S, Wallis Marsh J, Cintorino D, Biondo D, Castellese M, Scianna G, Luca A, Palazzo U, Arcadipane A, Burgio G, Vizzini G, Volpes R, Marcos A, Gridelli B. Living related liver transplant as resource to expand the donor pool. ASTS 7th annual state of the art winter symposium – Solving the organ shortage crisis: implications of expanding the donor pool. Marco Island, Florida. January 2007.
40. Volpes R, Gruttadauria S, Wallis Marsh J, Vizzini G, Palazzo U, Marcos A, Gridelli B. Living donor liver transplantation in adults: a single-center experience in Italy. 40° AISF annual general meeting. Rome, February 2007.
41. Burra P, Andreone P, Volpes R, Canova D, Cursaro C, Riili A, Fiorentino B, Bacci M, Guazzini S, Marzano A. Pharmacokinetics, efficacy and safety of hepatitis B immunoglobulin for intravenous and intramuscular use in prophylaxis of hepatitis B after liver transplantation. 5th Plasma Product Biotechnology Meeting. Elba, May 2007.
42. Gruttadauria S, Mandala' L, Petridis I, Luna E, Miraglia R, Caruso S, Vizzini G, Volpes R, Wallis Marsh J, Luca A, Marcos A, Gridelli B. Role of splenic artery embolization in the treatment of small for size syndrome in Adult to Adult Living Related Liver Transplantation. HPB Surgery. Verona, June 2007.
43. Volpes R, Gruttadauria S, Wallis Marsh J, Vizzini G, Palazzo U, Marcos A, Gridelli B. Living donor liver transplantation in adults: a single-center experience in Italy. 13° ESOT general meeting. Praga, September 2007.
44. Burra P, Andreone P, Volpes R, Canova D, Cursaro C, Riili A, Fiorentino B, Bacci M, Guazzini S, Marzano A. Pharmacokinetics, efficacy and safety of hepatitis B immunoglobulin for intravenous and intramuscular use in prophylaxis of hepatitis B after liver transplantation. 13° ESOT general meeting. Praga, September 2007.

45. Castellese M, Gruttadauria S, Scianna G, Cintonino D, Luca A, Palazzo U, Arcadipane A, Volpes R, Vizzini G, Gridelli B. Living related liver transplantation: a resource to increase the donor pool. 13° ESOT general meeting. Praga, September 2007.
46. Petridis I, Volpes R, Gruttadauria S, Wallis Marsh J, Vizzini G, Palazzo U, Marcos A, Gridelli B. Living donor liver transplantation in adults: a single-center experience in Italy. 27° National Congress of Gastroenterology. Salonicco, Ottobre 2007.
47. Petridis I, Gruttadauria S, Nadalin S, Pietrosi G, Filì D, Montalbano M, D'Antoni A, Volpes R, Vizzini G, Gridelli B. Liver Transplantation Using Donors Older Than 80: A Single Center Experience. AISF Monothematic Conference on Liver Transplantation, Bergamo October 2007.
48. Volpes R. Living donor liver transplantation in Italy. Impact on awaiting list. AISF Monothematic Conference on Liver Transplantation. Bergamo, October 2007.
49. Randisi L, Volpes R, Gruttadauria S, Castellese M, Rubino M, Minervini M, Vizzini G, Gridelli B. Usage of donor steatotic livers after a short-term intensive dietary treatment in living donor transplantation in adults. AISF Monothematic Conference on Liver Transplantation. Bergamo October, 2007.
50. Pietrosi G, Fili' D, Vizzini G, Lamonaca V, Panarello G, Minervini M, Conaldi PG, Volpes R, D'Antoni A, Montalbano M, Petridis I, Gridelli B. Human Herpesvirus 8 Infection (HHV-8) in Liver Transplant (LT) recipients: an emergent fatal complication in southern Italy. AISF Monothematic Conference on Liver Transplantation. Bergamo, October 2007.
51. Volpes R, Randisi L, Gruttadauria S, Castellese M, Rubino M, Minervini M, Vizzini G, Gridelli B. Usage of donors with steatosis after an intensive dietary treatment in living donor transplantation in adults. AASLD The Liver Meeting. Boston, November 2007.
52. Pietrosi G, Fili' D, Vizzini G, Lamonaca V, Panarello G, Minervini M, Conaldi PG, Volpes R, D'Antoni A, Montalbano M, Petridis I, Gridelli B. Human Herpesvirus 8 Infection (HHV-8) in Liver Transplant (LT) recipients: an emergent fatal complication in southern Italy. AASLD The Liver Meeting. Boston, November 2007.
53. Filì D, Vizzini G, Biondo D, Volpes R, Pietrosi G, D'Antoni A, Montalbano M, Petridis I, Luca A, Scardulla C, Hernandez-Baravoglia C, Gridelli B. Coronary artery disease screening in liver transplant candidates. AASLD The Liver Meeting. Boston, November 2007.
54. Petridis I, Gruttadauria S, Nadalin S, Pietrosi G, Filì D, Montalbano M, D'Antoni A, Volpes R, Vizzini G, Gridelli B. Liver Transplantation Using Donors Older Than 80: A Single Center Experience. Italian Society for Organ Transplantation (SITO). Modena, November 2007.
55. Marzano A, Volpes R, Burra P, Andreone P, Canova D, Cursaro C, Riilli A, Bacci M, Fiorentino B, Guazzini S. Pharmacokinetics, efficacy and safety of intramuscular and intravenous hepatitis B immunoglobulins combined with nucleoside analogues in prophylaxis of hepatitis B after liver transplantation. 41° AISF annual general meeting. Rome, February 2007.

56. Marzano A, Volpes R, Burra P, Andreone P, Canova D, Cursaro C, Riili A, Bacci M, Fiorentino B, Guazzini S. Pharmacokinetics, efficacy and safety of intramuscular and intravenous hepatitis B immunoglobulins combined with nucleoside analogues in prophylaxis of hepatitis B after liver transplantation. XIV FIMAD National Congress. Rimini, March 2008.
57. Volpes R, Marzano A, Burra P, Andreone P, Canova D, Cursaro C, Riili A, Bacci M, Fiorentino B, Guazzini S. Pharmacokinetics, efficacy and safety of intramuscular and intravenous hepatitis B immunoglobulins combined with nucleoside analogues in prophylaxis of hepatitis B after liver transplantation. 4th ELITA-ELTR winter meeting. Cortina, April 2008.
58. Marzano A, Andreone P, Volpes R, Canova D, Cursaro C, Riili A, Fiorentino B, Bacci M, Guazzini S, Burra P. Pharmacokinetics, efficacy and safety of intramuscular and intravenous hepatitis B immunoglobulins combined with nucleoside analogues in prophylaxis of hepatitis B after liver transplantation. 43rd Annual EASL Meeting. Milan, April 2008.
59. Andreone P, Volpes R, Burra P, Canova D, Cursaro C, Riili A, Bacci M, Fiorentino B, Guazzini S, Marzano A. Pharmacokinetics, efficacy and safety of intramuscular and intravenous hepatitis B immunoglobulins combined with nucleoside analogues in prophylaxis of hepatitis B after liver transplantation. Digestive Disease Week (DDW). San Diego, May 2008.
60. Andreone P, Volpes R, Burra P, Canova D, Cursaro C, Riili A, Bacci M, Fiorentino B, Guazzini S, Marzano A. Pharmacokinetics, efficacy and safety of intramuscular and intravenous hepatitis B immunoglobulins combined with nucleoside analogues in prophylaxis of hepatitis B after liver transplantation. American Transplant Congress (ATC). Toronto, May 2008.
61. Volpes R, Burra P, Andreone P, Canova D, Cursaro C, Riili A, Bacci M, Fiorentino B, Guazzini S, Marzano A. Pharmacokinetics, efficacy and safety of intramuscular and intravenous hepatitis B immunoglobulins combined with nucleoside analogues in prophylaxis of hepatitis B after liver transplantation. 2008 Joint International Congress of ILTS, ELITA & LICAGE general meeting. Paris, July 2008.
62. Randisi L, Rubino M, Volpes R, Gruttadauria S, Castellese M, Vizzini G, Minervini M, Gridelli B. Short-term intensive dietary treatment for a safe usage of steatotic donors in living donor transplantation. 30th ESPEN Meeting. Firenze, September 2008.
63. Petridis I, Tarantino I, Barresi, Traina M, Volpes R, Gruttadauria S, Marsh J, Vizzini G, Palazzo U, Marcos A, Gridelli B. Diagnosis and treatment of biliary complications after liver transplantation: the ISMETT-UPMC experience. 16th UEGW Meeting, Vienna, October 2008.
64. Petridis I, D'Antoni A, Volpes R, Luca A, Vizzini G, Miraglia R, Gridelli B, Bosch J. Transjugular intrahepatic portosystemic shunt (TIPS) placement in cirrhotic patients and prognostic factors of post-TIPS liver dysfunction. 28^o National Congress of Gastroenterology. Athens, Novembre 2008.

65. Tarantino I, Traina M, Barresi L, Petridis I, Volpes R, Gridelli B. Full covered metal biliary stents for treatment of biliary complications after liver transplantation. 15° SIGEAIGO-FISMAD Meeting, Milano, March 2009.
66. Traina M, Volpes R, Tarantino I, Petridis I, Barresi L, Gridelli B. Full covered metal biliary stents for treatment of biliary complications after liver transplantation. Digestive Disease Week (DDW). Chicago, May 2009.
67. Belli L, Volpes R, Graziadei I, Starkel P, Burroughs AK, Burra P, Fagiuoli S, Alberti AB, Guido M, Pasulo L, Vogel W, Gridelli B, Cillo U, De Carlis L, Pinzello GB. PEG-IFN-alfa 2b with Ribavirin for the treatment of mild-moderate recurrent hepatitis C after liver transplantation (LT) : impact on fibrosis progression. A multicenter randomized controlled study. 14th ESOT Congress. Paris, August 2009.
68. Petridis I, Gruttadauria S, D'Antoni A, Volpes R, Vizzini G, Gridelli B. Extended criteria donor liver grafts are the answer for expanding the liver donor pool: results of a single Center. 29th Hellenic Congress of Gastroenterology. Salonicco, Ottobre 2009.
69. Belli L, Volpes R, Graziadei I, Starkel P, Burroughs AK, Burra P, Fagiuoli S, Alberti AB, Guido M, Pasulo L, Vogel W, Gridelli B, Cillo U, De Carlis L, Pinzello GB. PEG-IFN-alfa 2b with Ribavirin for the treatment of mild-moderate recurrent hepatitis C after liver transplantation (LT) : impact on fibrosis progression. A multicenter randomized controlled study. AASLD The Liver Meeting. Boston, November 2009.
70. Petridis I, Miraglia R, Gruttadauria S, Pagano D, Volpes R, Luca A, Vizzini G, Palazzo U, Gridelli B. Portal hypertension after liver transplantation. 2010 International Congress of ILTS. Hong-Kong, June 2010.
71. Volpes R, Gruttadauria S, Galatioto L, Vizzini G, Gridelli B. Donor selection for living donor liver transplantation: a single Center experience in Italy. 5th International Conference: Living Donor Abdominal Organ Transplantation. Firenze, June 2010.
72. Miraglia R, Maruzelli L, Minervini M, Vizzini G, Volpes R, Gruttadauria S, Caruso S, Luca A, Gridelli B. Transjugular liver biopsy in liver transplant patients using an 18 gauge automated core biopsy needle: review of 183 consecutive procedures. 12th Congress of the Middle East Society for Organ Transplantation (MESOT). Tunisi, October 2010.
73. Miraglia R, Petridis I, Maruzelli L, Minervini M, Gruttadauria S, Vizzini G, Volpes R, Luca A, Gridelli B. Recurrence of sinusoidal portal hypertension after liver transplantation. 12th Congress of the Middle East Society for Organ Transplantation (MESOT). Tunisi, October 2010.
74. Tarantino I, Traina M, Volpes R, Petridis I, Barresi L, Luca A, Gridelli B. Fully covered self-expandable metallic stents in biliary complication after liver transplantation: efficacy and safety in a large cohort of treated patients. Digestive Disease Week (DDW) - American Society of Gastroenterology and Endoscopy (ASGE). Chicago, May 2011.
75. Tarantino I, Traina M, Barresi L, Curcio G, Mocciaro F, Volpes R, Petridis I, Gridelli B. Stent metallici totalmente ricoperti autoespandibili nel trattamento delle complicanze biliari post-trapianto di fegato: valutazione di efficacia e sicurezza in una ampia coorte

- di pazienti. XVII Congresso Internazionale Malattie Digestive (FISMAD). Torino, March 2011.
76. Tarantino I, Traina M, Barresi L, Curcio G, Mocciaro F, Volpes R, Petridis I, Gridelli B. Fully covered self-expandable metallic stents in biliary complication after liver transplantation: efficacy and safety in a large cohort of treated patients. 46th EASL meeting. Berlino, March 2011.
 77. Filì D, Vizzini G, Pietrosi G, Galatioto L, Palazzo U, Volpes R, Gridelli B. Cytomegalovirus infection in adult liver transplantation: is a strict surveillance protocol for all recipients warranted?. 46th EASL meeting. Berlino, March 2011.
 78. Burra P, Caccamo L, Volpes R, Ercolani G, Scuderi V, Pacilio R, Magni B, Boccagni P, Strignano P, Cibelli A, De Martin E, Lazzaro S, Calise F, Pinna A, Rossi G, Di Costanzo G, Carrai P, Cillo U, Salizzoni M, Franciosi M, Nicolucci A. Development and validation of an instrument evaluating the impact of anti HBV Immunoglobulin therapy (HBIG) on quality of life (HRQOL) in liver transplant (LT) patients. 15th ESOT Congress. Glasgow, September 2011.
 79. Petridis I, Miraglia R, Gruttadauria S, Volpes R, Luca A, Vizzini G, Palazzo U, Gridelli B. Risk factors for HCC recurrence after liver transplantation. 31st Hellenic Congress of Gastroenterology, Salonicco, October 2011.
 80. Volpes R, Galatioto L, Vizzini G, Gridelli B. Efficacy and feasibility of conversion to subcutaneous (SC) human HBV-immunoglobulins (HBIG) for the prophylaxis of HBV recurrence after liver transplantation. EASL Special Conference on Liver Transplantation, Lisbona, December 2011.
 81. Volpes R. Current treatment options of HBV recurrence after liver transplantation. 8th AISF Single Topics Conference on Infections in End Stage Liver Diseases and Liver Transplantation. Bergamo, January 2012.
 82. Volpes R. Current treatment options of HBV recurrence after liver transplantation. 1st International Congress on Viral Hepatitis and Organ Transplantation. Varese, April 2012.
 83. Volpes R. Prophylaxis of HBV recurrence after liver transplantation. 47th Annual EASL Meeting. Barcelona, April 2012.
 84. Volpes R, Galatioto L, Vizzini G, Gridelli B. "Early" conversion to subcutaneous (SC) human HBV-immunoglobulins (HBIG) is safe and effective in preventing HBV recurrence after liver transplantation. 3rd SISQT, Milano, May 2012.
 85. Volpes R, Gruttadauria S, Spada M, Galatioto L, Vizzini G, Gridelli B. Donor selection for living donor liver transplantation: a single Center experience in Italy. 5th International Conference: Living Donor Abdominal Organ Transplantation. 3rd SISQT, Milano, May 2012.
 86. Volpes R, Galatioto L, Vizzini G, Gridelli B. "Early" conversion to subcutaneous (SC) human HBV-immunoglobulins (HBIG) is safe and effective in preventing HBV recurrence after liver transplantation. 17th International Congress of ILTS. San Francisco, May 2012.

87. Caccamo L, Franciosi M, De Simone P, Pinna A, Di Costanzo G, Volpes R, Scuderi V, Strignano P, Boccagni P, Burra P, Nicolucci A. Impact of anti-HBV immunoglobulins on quality of life after liver transplantation. 17th International Congress of ILTS. San Francisco, May 2012.
88. Volpes R, Galatioto L, D'Antoni A, Filì D, Petridis I, Pietrosi G, Corsale S, Sapere MC, Vizzini G, Gridelli B. Efficacy and safety of tacrolimus conversion from twice-daily (Prograf®) to once-daily prolonged-released (Advagraf®) in liver transplantation. An Italian single-center experience. 24th International Congress of The Transplantation Society (TTS), July 2012, Berlin.
89. Volpes R. Consensus Conference on Outcome Measures in Liver Transplantation in Italy: first step. Torino, October 2012.
90. Volpes R. HBV recurrence after liver transplantation: prophylaxis and treatment. 4th International Congress on Infections and Organ Transplantation. Stresa, May 2013.
91. Volpes R. Consensus Conference on Outcome Measures in Liver Transplantation in Italy: final step. Palermo, May 2013.
92. Volpes R. Efficacy and safety of tacrolimus conversion from twice-daily (Prograf®) to once-daily prolonged-released (Advagraf®) in liver transplantation. Advagraf/Astagraf global advisory board meeting. London, September 2013.
93. Volpes R. Limits of MELD in the organ allocation (MELD exceptions). 47th Annual AISF Meeting. Rome, February 2014.
94. Volpes R. Prevention of HBV recurrence after liver transplantation. 2nd International Congress on Viral Hepatitis and Organ Transplantation. Stresa, May 2014.
95. Volpes R. HBIG and antiviral therapy in Hepatitis B liver transplant prophylaxis: model comparison. 9th AISF Single Topic Conference. Milan, June 2014.
96. Volpes R. Current treatment options of HBV recurrence after liver transplantation. The role of Human Immunoglobulins. 5th International Congress on Infections and Organ Transplantation. Varese, April 2015.
97. Volpes R. TIPS and liver transplantation 11th AISF Special Conference. Bergamo, June 2015.
98. Petridis I, Miraglia R, Pagano D, Gruttadauria S, Volpes R, Vizzini G, Spada M, Luca A, Gridelli B. Acute liver failure secondary to HBV infection as an emergent cause for Liver Transplantation. A single center experience in a southern Mediterranean region of Italy. 18th International Congress of ILTS. Chicago, July 2015.
99. Volpes R, Burra P, Germani G, Strignano P, Rizza G, Migliaccio C, Calise F, Tamè M, Pinna AD, Manini M, Caccamo L, Carrai P, De Simone P, Valentini MF, Lupo LG, Cordone

- G, Picciotto F, Nicolucci A. Switching from intramuscular or intravenous to subcutaneous hepatitis B immune globulin improves the quality of life of liver transplant recipients. 17th ESOT Meeting. Bruxelles, September 2015.
100. Calvaruso V, Cacciola I, Russello M, Davì A, Scifo G, Volpes R, Montineri A, Prestileo T, Madonna S, Malizia G, Digiacomo A, Bertino G, Magro A, Licata A, Cacopardo B, Salvo A, Guarneri L, Scalisi I, Mannino G, Colletti P, Cartabellotta F, Portelli V, Raimondo G, Craxì A, Di Marco V on behalf of RESIST-HCV (Rete Sicilia Selezione Terapia – HCV). Treatment of elderly HCV patients with severe fibrosis: safety and efficacy data from RESIST-HCV, a large regional database. AASLD The Liver Meeting. Boston, November 2016.
 101. Madonna S, Calvaruso V, Cacciola I, Russello M, Davì A, Scifo G, Volpes R, Montineri A, Prestileo T, Malizia G, Digiacomo A, Bertino G, Magro A, Licata A, Cacopardo B, Salvo A, Guarneri L, Scalisi I, Mannino G, Colletti P, Cartabellotta F, Portelli V, Cannizzaro M, Raimondo G, Craxì A, Di Marco V on behalf of RESIST-HCV (Rete Sicilia Selezione Terapia – HCV). Efficacy and safety of DAA regimens in HCV genotype 1b patients with compensated cirrhosis: data of RESIST-HCV Cohort. AASLD The Liver Meeting. Boston, November 2016.
 102. Calvaruso V, Cacciola I, Licata A, Madonna S, Benigno R, Bronte F, Petta S, Malizia G, Bertino G, Di Stefano M, Volpes R, Montineri A, Digiacomo A, Alaimo G, Cacopardo B, Guarneri L, Scalisi I, Mazzola G, Cartabellotta F, Portelli V, Russello M, Squadrito G, Raimondo G, Craxì A, Di Marco V on behalf of RESIST-HCV (Rete Sicilia Selezione Terapia – HCV). Non-invasive tools to ruling out large varices: RESIST-HCV vs Baveno VI criteria in a large cohort of patients with HCV cirrhosis. 50th Annual AISF Meeting. Rome, February 2017.
 103. Cacciola I, Petta S, Di Stefano M, Cannavò MR, Davì A, Madonna S, Calvaruso V, La Rocca L, Di Lorenzo F, Digiacomo A, Bertino G, Licata A, Benanti F, Volpes R, Guarneri L, Averna A, Scalisi I, Iacobello C, Colletti P, Cartabellotta F, Portelli V, Russello M, Scifo G, Squadrito G, Raimondo G, Craxì A, Di Marco V on behalf of RESIST-HCV (Rete Sicilia Selezione Terapia – HCV). Efficacy of oral Direct Acting Antivirals for the treatment of chronic hepatitis/cirrhosis due to hepatitis C virus infection: the real-life experience of the Sicily Registry. 50th Annual AISF Meeting. Rome, February 2017.
 104. Cabibbo G, Cacciola I, Cannavò MR, Madonna S, Calvaruso V, Petta S, Di Stefano M, La Rocca L, Prestileo T, Tinè F, Digiacomo A, Bertino G, Giannitrapani L, Benanti F, Davì A, Volpes R, Guarneri L, Averna A, Scalisi I, Iacobello C, Mazzola G, Cartabellotta F, Portelli V, Russello M, Scifo G, Squadrito G, Raimondo G, Craxì A, Di Marco V, Cammà C on behalf of RESIST-HCV (Rete Sicilia Selezione Terapia – HCV). Risk of Hepatocellular Carcinoma (HCC) Recurrence in HCV cirrhotic patients treated with direct acting antivirals (DAAs). 50th Annual AISF Meeting. Rome, February 2017.
 105. Calvaruso V, Cacciola I, Licata A, Madonna S, Benigno R, Bronte F, Petta S, Malizia G, Bertino G, Di Stefano M, Volpes R, Montineri A, Digiacomo A, Alaimo G, Cacopardo B, Guarneri L, Scalisi I, Mazzola G, Cartabellotta F, Portelli V, Russello M, Squadrito G, Raimondo G, Craxì A, Di Marco V on behalf of RESIST-HCV (Rete Sicilia Selezione Terapia – HCV). Non-invasive tools to ruling out large varices: RESIST-HCV vs Baveno VI criteria in a large cohort of patients with HCV cirrhosis. 52nd Annual ILC-EASL Meeting. Amsterdam, April 2017.

106. Cacciola I, Petta S, Di Stefano M, Cannavò MR, Davì A, Madonia S, Calvaruso V, La Rocca L, Di Lorenzo F, Digiacoimo A, Bertino G, Licata A, Benanti F, Volpes R, Guarneri L, Averna A, Scalisi I, Iacobello C, Colletti P, Cartabellotta F, Portelli V, Russello M, Scifo G, Squadrito G, Raimondo G, Craxì A, Di Marco V on behalf of RESIST-HCV (Rete Sicilia Selezione Terapia – HCV). Efficacy of oral Direct Acting Antivirals for the treatment of chronic hepatitis/cirrhosis due to hepatitis C virus infection: the real-life experience of the Sicily Registry. 52nd Annual ILC-EASL Meeting. Amsterdam, April 2017.
107. Madonia S, Calvaruso V, Filomia R, Cannavò MR, Di Stefano M, Russello M, Davì A, Scifo G, Volpes R, Montineri A, Ficalora R, Malizia G, Digiacoimo A, Bertino G, Alaimo G, Licata A, Cacopardo B, Averna A, Guarneri L, Scalisi I, Colletti P, Cartabellotta F, Savalli F, Cannizzaro M, Raimondo G, Craxì A, Di Marco V on behalf of RESIST-HCV (Rete Sicilia Selezione Terapia – HCV). Efficacy and safety of 12-week DAA regimens in HCV genotype 1b patients with compensated cirrhosis: data of RESIST-HCV Cohort. 52nd Annual ILCEASL Meeting. Amsterdam, April 2017.
108. Cabibbo G, Cacciola I, Cannavò MR, Madonia S, Calvaruso V, Petta S, Di Stefano M, La Rocca L, Prestileo T, Tinè F, Digiacoimo A, Bertino G, Giannitrapani L, Benanti F, Davì A, Volpes R, Guarneri L, Averna A, Scalisi I, Iacobello C, Mazzola G, Cartabellotta F, Portelli V, Russello M, Scifo G, Squadrito G, Raimondo G, Craxì A, Di Marco V, Cammà C on behalf of RESIST-HCV (Rete Sicilia Selezione Terapia – HCV). Risk of Hepatocellular Carcinoma (HCC) Recurrence in HCV cirrhotic patients treated with direct acting antivirals (DAAs). 52nd Annual ILC-EASL Meeting. Amsterdam, April 2017.
109. Cacciola I, Petta S, Di Stefano M, Cannavò MR, Davì A, Madonia S, Calvaruso V, La Rocca L, Di Lorenzo F, Digiacoimo A, Bertino G, Licata A, Benanti F, Volpes R, Guarneri L, Averna A, Scalisi I, Iacobello C, Colletti P, Cartabellotta F, Portelli V, Russello M, Scifo G, Squadrito G, Raimondo G, Craxì A, Di Marco V on behalf of RESIST-HCV (Rete Sicilia Selezione Terapia – HCV). Efficacy of oral Direct Acting Antivirals for the treatment of chronic hepatitis/cirrhosis due to hepatitis C virus infection: the real-life experience of the Sicily Registry. 52nd Annual ILC-EASL Meeting. Amsterdam, April 2017.
110. Belli L, Berenguer M, Cortesi PA, Facchetti R, Strazzabosco M, Perricone G, Rockenschaub S-R, Martini S, Morelli C, Donato F, Volpes R, Pageaux P, Coilly A, Fagiuoli S, Berlakovich G, Monico S, Vinaixa C, Polak W, Duvoux C. Delisting of liver transplant candidates with chronic HCV infection after viral eradication: outcome after delisting. A European study. 52nd Annual ILC-EASL Meeting. Amsterdam, April 2017.
111. Di Francesco F, Bonsignore P, Martucci D, Pagano D, Cintorino D, Liotta R, Arcadipane A, Volpes R, Luca A, Gruttadauria S. Normothermic machine perfusion using an air/oxygen mixer: reconditioning a marginal donor liver. 12th International Congress of EAHPBA (European-African hepato-pancreato-biliary association. Mainz, May 2017.
112. Petridis I, Volpes R, D'Antoni A, Pietrosi G, Maruzzelli L, Miraglia R, Luca A. A novel TIPS-controlled expansion stent for the treatment of severe portal hypertension. A single center experience. AASLD The Liver Meeting. Washington, October 2017.
113. Pagano D, Barbera F, Conaldi PG, Cintorino D, Di Francesco F, Tropea A, Seidita A, Volpes R, Luca A, Gruttadauria S. Predizione del rischio di recidiva di HCC dopo trapianto di fegato mediante analisi monocentrica dello squilibrio allelico. 41st SITO Meeting, Cagliari, Novembre 2017.

114. Miraglia R, Maruzzelli L, Petridis I, Volpes R, Tuzzolino F, Luca A. Transjugular intrahepatic portosystemic shunt using a new controlled expansion e-PTFE covered stent: single center experience with short term follow-up. Cardiovascular and Interventional Radiological Society of Europe, Lisbona, Maggio 2018.
115. Brancaccio G, Martini S, Ciancio A, Volpes R, Di Stefano M, Masarone V, Messina C, Montineri M, Biolato M, Brillanti S, Claar E, Dell'Isola C, Lionetti R, Montalbano M, Picciotto A, Sollima S, Taibi E, Teti E, Ucciferri C, Cirillo P, Gaeta GB. Sofosbuvir/velpatasvir ± ribavirin for retreatment of patients with chronic hepatitis C virus (HCV) infection failing to a previous DAA combination regimen. EASL, Lisbona, April 2018.
116. Brancaccio G, Martini S, Ciancio A, Volpes R, Di Stefano M, Masarone V, Messina C, Montineri M, Biolato M, Brillanti S, Claar E, Dell'Isola C, Lionetti R, Montalbano M, Picciotto A, Sollima S, Taibi E, Teti E, Ucciferri C, Cirillo P, Gaeta GB. Sofosbuvir/velpatasvir ± ribavirin for retreatment of patients with chronic hepatitis C virus (HCV) infection failing to a previous DAA combination regimen. AASLD, San Francisco, Novembre 2018.
117. Brancaccio G, Martini S, Ciancio A, Volpes R, Di Stefano M, Masarone V, Messina C, Montineri M, Biolato M, Brillanti S, Claar E, Dell'Isola C, Lionetti R, Montalbano M, Picciotto A, Sollima S, Taibi E, Teti E, Ucciferri C, Cirillo P, Gaeta GB. Sofosbuvir/velpatasvir ± ribavirin in Hepatitis C patients failing DAA regimens. CROI, Seattle, March 2019.
118. Avolio WA, Burra P, Cillo U, Toniutto PL, Risaliti A, Morelli MC, Cescon M, Volpes R, Mazzaferro V, Belli L, Faggioli S, Romagnoli R, De Simone P, et al. Different perceptions of sustainable case-mix for liver transplantation between surgeons and hepatologists. An Italian multicenter study. Annual ILTS Meeting, Toronto, May 2019.
119. Pavone G, Martucci G, Li Petri S, Panarello G, Tuzzolino F, Piacente C, Papeo A, Bonicolini E, Spina C, Burgio G, Volpes R, Vizzini G, Gruttadauria S, Arcadipane A. CRRT after orthotopic liver transplantation. 39° Annual ISICEM, Brussels, March 2019.
120. Maccora S, Gruttadauria S, Volpes R, Lo Re V. Pisa Syndrome as an unusual presentation of portosystemic encephalopathy: a case report. 50° Annual Meeting of Italia Society of Neurology.
121. Petridis I, Berzigotti A, Bosh J, Maruzzelli L, Miraglia R, Tuzzolino F, Volpes R. Sarcopenia as predictor for mortality after transjugular intrahepatic portosystemic shunt creation in patients with refractory ascites. AISF Annual Meeting, Rome, February 2020
122. Petridis I, Berzigotti A, Bosh J, Maruzzelli L, Miraglia R, Tuzzolino F, Volpes R. Sarcopenia as predictor for mortality after transjugular intrahepatic portosystemic shunt creation in patients with refractory ascites. EASL-ILC Annual Meeting, London, April 2020
123. Maruzzelli L, Berzigotti A, Bosh J, Petridis I, Miraglia R, Tuzzolino F, Volpes R. Sarcopenia as predictor for mortality after transjugular intrahepatic portosystemic shunt creation in patients with refractory ascites. ESGAR (European Society of Gastrointestinal and Abdominal Radiology), 31th Annual Meeting, Amsterdam, May 2020
124. Miraglia R, Berzigotti A, Bosh J, Petridis I, Maruzzelli L, Tuzzolino F, Volpes R. Sarcopenia as predictor for mortality after transjugular intrahepatic portosystemic shunt creation

in patients with refractory ascites. CIRSE ESGAR (Cardiovascular and Interventional Radiological Society of Europe), Annual Meeting, Munich, September 2020.

125. Petridis I, Miraglia R, Maruzzelli L, Wan T, Berzigotti A, Bosh J, *Volpes R*. Sarcopenia predicts mortality after transjugular intrahepatic portosystemic shunt (TIPS) creation in cirrhotic patients with refractory ascites. ILC-EASL Annual Meeting, London, August 2020.
126. *Volpes R*, Petridis I. Long-term full adherence and high efficacy against HBV recurrence after liver transplantation by using long-life parenteral HBV-immunoglobulins (HBIG) in combination with oral antivirals. ILTS, ELITA and LICAGE Annual Meeting, Istanbul, June 2020.
127. *Volpes R*, Petridis I. Long-term full adherence and high efficacy against HBV recurrence after liver transplantation by using long-life parenteral HBV-immunoglobulins (HBIG) in combination with oral antivirals. ILTS, ELITA and LICAGE 2021 Virtual Meeting, May 2021.
128. Belli L, Duvoux C, Artzner T, Bernal W, Conti S, Cortesi PA, Sacleux SC, Pageaux GP, Radenne S, Trebicka J, Fernandez J, Perricone G, Piano S, Nadalin S, Morelli MC, Martini S, Polac W, Zieniewicz K, Toso C, Berenguer M, Iegri C, Invernizzi F, *Volpes R*, Karam V, Faitot F, Rabinovich L, Saliba F, Meunier L, Lesurtel M, Uschner FE, Fondevila C, Michard B, Coilly A, Meszaros M, Poinso D, Schnitzbauer A, De Carlis LG, Fumagalli R, Angeli P, Arroyo V, Jalan R. Location and allocation: inequity of access to liver transplantation for patients with acute-on-chronic liver failure grade 3 (ACLF-3) across Europe. The Liver Meeting. Anaheim, November 2021.

“Ai sensi e per effetto del D.Lgs. n. 196/2003 ‘Codice in materia di protezione dei dati personali e sensibili’, autorizzo al trattamento dei dati e delle informazioni contenute nel curriculum vitae ai fini del procedimento ECM, consapevole che il CV verrà incluso nell'allegato all'atto della validazione della richiesta di accreditamento, e che sarà visibile nella Banca Dati del sito ECM, accessibile a tutti gli utenti e tramite INTERNET (motori di ricerca).

Autorizzo altresì il trattamento ai fini della trasmissione (successiva allo svolgimento dell'evento formativo) alla Commissione Nazionale per la Formazione Continua”.

Data
21/09/2023

Firma
Dr. Riccardo Volpes